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INTRODUCTION 
The federal food, drug, and cosmetic act defines a drug as follows: 
The term “drug” means (a) articles recognized in the official United states 
pharmacopoeia, official homoeopathic pharmacopoeia of the united states, or 
official national formulary.; and (b) articles  intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease in man and other animals; and 
(c) articles (other than food) intended to affect the structure or any function of the 
body of man or other animals; and (d) articles intended for use as a component of 
any articles specified in (a), (b) or (c).1 
Pharmaceutical analysis is the branch of chemistry involved in separating, 
identifying and determining the relative amounts of the components making up a 
sample of matter. It is mainly involved in the qualitative identification or detection 
of compounds and quantitative measurements of the substances present in bulk 
drug and pharmaceutical preparations.2 
In general terms, pharmaceutical analysis comprises those procedures 
necessary to determine the “identity, strength, quality, and purity” of such articles. 
For practical reasons, however, it is proper to broaden the scope of this definition 
to include the analysis of raw materials. Analytical chemists in the pharmaceutical 
industry, as well as in those chemical industries that produce pharmaceutical raw 
materials, must perform such analyses. The raw materials employed in the 
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production of modern drugs and the intermediates appearing during research, 
development and synthesis, involve thousands of diverse organic compounds. The 
pharmaceutical analyst must, therefore, have a firm grounding in basic organic 
analysis in addition to special skill in the quality evaluation of drug products. 
Laboratories requiring pharmaceutical analysis may be classified as follow: 
1. government regulatory agencies, 
2. manufacturers of drugs, 
3. manufacturers of raw materials for drugs, 
4. university and other non-commercial research centres, 
5. Consulting laboratories. 
The principal federal agencies that regulate the drug industry are the food 
and drug administration (F.D.A) and the U.S. public health service. The latter is 
responsible for biological products such as vaccines and antitoxins that are tested 
largely by biological rather than chemical methods. 
The food and drug administration, an agency of the department of health, 
education and welfare, administers and enforces the federal food, drug, and 
cosmetic Act. It is important that everyone concerned with medicinal products, 
whether in research, production, control, prescribing, or dispensing, understand 
this law, the reasons the congress had for its enactment, and the machinery 
provided its enforcement. This is especially so for pharmaceutical analysts, since 
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otherwise they can have no adequate appreciation of their front-line role as 
guardians of the public health1. 
In a modern industrialized society the analytical chemist has a very 
important role to play. Thus most manufacturing industries rely upon both 
qualitative and quantitative chemical analysis to ensure that the raw materials used 
meet certain specifications, and also to check the quality of the final product. The 
examination of raw materials is carried out to ensure that there are no unusual 
substances present which might be deleterious to the manufacturing process or 
appear as a harmful impurity in the final product. Further, since the value of the 
raw material may be governed by the amount of the required ingredient which it 
contains, a quantitative analysis is performed to establish the proportion of the 
essential component: this procedure is often referred to as assaying. The final 
manufactured product is subject to quality control to ensure that its essential 
components are present within a pre-determined range of composition, whilst 
impurities do not exceed certain specified limits. 
Quality Assurance plays a central role in determining the safety and 
efficacy of medicines. Highly specific and sensitive and analytical techniques hold 
the key to the design, development, standardization and quality control of 
medicinal products. They are equally important in pharmacokinetics and in drug 
metabolism studies, both of which are fundamental to the assessment of 
bioavailability and the duration of clinical response. However modern concepts of 
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quality differs and concerned not only with chemical purity, but also with those 
other characterstics of pharmaceutical materials which may influence safety, 
efficacy, formulation and processing of medicines.3 
TYPES OF ANALYSIS: 
Important factors which must be taken into account when selecting an 
appropriate method of analysis include 
(a) The nature of the information which is sought, 
(b) The size of sample available and the proportion of the constituent to be 
determined, and 
(c) The purpose for which the analytical data are required. 
The nature of the information sought may involve requirement for very 
detailed data, or alternatively, results of a general character may suffice with 
respect to the information which is furnished. 
Different types of chemical analysis may be classified as follows: 
Proximate analysis, in which the amount of each element in a sample is 
determined with no concern as to the actual compounds present; 
Partial analysis, which deals with the determination of selected constituents in the 
sample; 
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Trace constituent analysis, a specialized instance of partial analysis in which we 
are concerned with the determination of specified components present in minute 
quantity; 
Complete analysis, when the proportion of each component of the sample is 
determined. 
On the basis of sample size, analytical methods are often classified as: 
1. Macro, the analysis of quantities of 0.1g or more; 
2. Meso(semi micro),dealing with quantities ranging from 10-2g to 10-1g ; 
3. Micro, for quantities in the range 10-3 g to 10-2 g; 
4. Sub micro, for samples in the range 10-4 g to 10-3 g; 
5. Ultra micro, for quantities below 10-4 g. 
The term ‘semi micro’ given as an alternative name for classification (2) is 
not very apt, referring as it does to samples larger than micro. 
A major constituent is one accounting for 1-100 percent of the sample 
under investigation; a minor constituent is one present in the range 0.01-1percent; 
a trace constituent is one present at a concentration of less than 0.01percent. with 
the development of increasingly sophisticated analytical techniques it has become 
possible to determine substances present in quantities much lower than the 0.01% 
upper level set for trace constituents.  It is therefore necessary to make further 
subdivisions: trace corresponds to 102-104 µg per gram, or 102- 104 parts per 
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million (ppm),  micro trace to 102-10-1pg per gram, (10-4-10-7 ppm), nanotrace to 
102-10-1fm per gram (10-7-10-10ppm). 
When the sample weight is small (0.1-1.0mg), the determination of a trace 
component at the 0.01 percent level may be referred to as sub trace analysis. If the   
trace component is at the microtrace level, the analysis is termed submicrotrace. 
With a still smaller sample (not larger than 0.1mg) the determination of a 
component at the trace level is referred to as ultra trace analysis, whilst with a 
component at the microtrace level, the analysis is referred to as ultra-microtrace. 
The purpose for which the analytical data are required may perhaps be 
related to process control and quality control. In such circumstance the objective is 
checking that raw materials and finished products conform to specification, and it 
may also be concerned with monitoring various stages in a manufacturing process. 
For this kind of determination methods must be employed which are quick and 
which can be readily adapted for routine work: in this area instrumental methods 
have an important role to play, and in certain cases may lend themselves to 
automation. On the other hand, the problem may be one which requires detailed 
consideration and which may be regarded as being more in the nature of a research 
topic. 
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COMMON TECHNIQUES: 
The main techniques employed in quantitative analysis are based upon: 
• The quantitative performance of suitable chemical reactions and either measuring 
the  amount of reagent needed to complete the reaction, or ascertaining the 
amount of reaction product obtained; 
• Appropriate electrical measurements(e.g. potentiometry); 
• The measurement of certain optical properties (e.g. absorption spectra). 
In some cases, a combination of optical or electrical measurements and 
quantitative chemical reaction (e.g. amperometric titration) may be used. 
The quantitative execution of chemical reactions is the basis of the 
traditional or ‘classical’ methods of chemical analysis: gravimetry, titrimetry, and 
volumetry. In gravimetric analysis the substance being determined is converted 
into an insoluble precipitate which is collected and weighed, or in the special case 
of electrogravimetry electrolysis is carried out and the material deposited on one 
of the electrodes is weighed. 
In titrimetric analysis the substance to be determined is allowed to react 
with an appropriate reagent added as a standard solution, and the volume of 
solution needed for complete reaction is determined. 
The common types of reaction which are used in titrimetry are: 
(a) Neutralization (acid-base) reactions; 
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(b) Complex-forming reactions; 
(c) Precipitation reactions; 
(d) Oxidation-reduction reactions. 
Volumetry is concerned with measuring the volume of gas evolved or 
absorbed in a chemical reaction. 
Electrical methods of analysis (apart from electrogravimetry referred to 
above) involve the measurement of current, voltage or resistance in relation to the 
concentration of a certain species in solution. 
Techniques which can be included under this general heading are: 
1. Voltammetry (measurement of current at a micro-electrode at a specified 
voltage); 
2. Coulometry (measurement of current and time needed to complete an 
electrochemical reaction or to generate sufficient material to react 
completely with a specified reagent); 
3. Potentiometry (measurement of the potential of an electrode in equilibrium 
with an ion to be determined) 
4. Conductimetry (measurement of the electrical conductivity of a solution). 
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Optical methods of analysis are dependent either upon 
• Measurement of the amount of radiant energy of a particular wavelength 
absorbed by the sample, or 
• The emission of radiant energy and measurement of the amount of energy 
of a particular wavelength emitted. 
Absorption methods are usually classified according to the wavelength 
involved as 
(a) Visible spectrophotometry (colorimetry), 
       (b) Ultraviolet spectrophotometry, and 
       (c) Infrared spectrophotometry. 
Atomic absorption spectroscopy involves atomizing the specimen, often by 
spraying a solution of the sample into a flame, and then studying the absorption of 
radiation from an electric lamp producing the spectrum of the element to be 
determined. 
Although not strictly absorption methods in the sense in which the term is 
usually employed, turbidimetric and nephelometric methods which involve 
measuring the amount of light stopped or scattered by a suspension should also be 
mentioned at this point. 
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Emission methods involve subjecting the sample to heat or electrical 
treatment so that atoms are raised to excited states causing them to emit energy: it 
is the intensity of this emitted energy which is measured.2, 4 
Table: 1. List of Common Solvents used in UV Spectroscopy5 
Solvents Cut off  wavelength(nm) 
Acetonitrile 190 
Water 191 
Cyclohexane 195 
Hexane 201 
Methanol 203 
Ethanol 204 
Ether 215 
Methylene dichloride 220 
Chloroform 237 
Carbon tetrachloride 257 
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The common excitation techniques are: 
Emission spectroscopy, where the sample is subjected to an electric arc or 
spark plasma and the light emitted (which may extend into the ultraviolet region) 
is examined; 
Flame photometry, in which a solution of the sample is injected into a 
flame,which evaporates the solvent,sublimates and atomizes the metal. Light is 
emitted at characteristic wavelength for each metal. 
Fluorimetry, in which a suitable substance in solution (commonly a 
metalfluorescent reagent complex) is excited by irradiation with visible or 
ultraviolet radiation. 
Chromatography is a separation process employed for the separation of 
mixtures of substances. It is widely used for the identification of the components 
of mixtures, but, it is often possible to use the procedure to make quantitative 
determinations, particularly when using gas chromatography (GC) and high 
performance liquid chromatography (HPLC). 
INSTRUMENTAL METHODS: 
The methods dependent upon measurement of an electrical property, and 
those based upon determination of the extent to which radiation is absorbed or 
upon assessment of the intensity of emitted radiation, all require the use of a 
suitable instrument ,e.g. polarograph, spectrophotometer, etc., and in consequence 
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such methods are referred to as ‘instrumental methods’. Instrumental methods are 
usually much faster than purely chemical procedures, they are normally applicable 
at concentrations far too small to be amenable to determination by classical 
methods, and they find wide application in industry .in most cases a 
microcomputer can be interfaced to the instrument so that absorption curves, 
polarograms, titration curves, etc., can be plotted automatically, and in fact, by the 
incorporation of appropriate servo-mechanisms, the whole analytical process may, 
in suitable cases, completely automated. 
Despite the advantages possessed by instrumental methods in many 
directions, their widespread adoption has not rendered the purely chemical or 
‘classical’ methods obsolete; the situation is influenced by three main factors. 
The apparatus required for classical procedures is cheap and readily 
available in all laboratories, but many instrument are expensive and their use will 
only be justified if numerous samples have to be analyzed, or when dealing with 
the determination of substances present in minute quantities (trace,subtrace or 
ultratrace analysis).With instrumental methods it is necessary to carry out a 
calibration operation using a sample of material of know composition as reference 
substance. 
Whilst an instrumental method is ideally suited to the performance of a 
large number of routine determinations, for an occasional, non-routine, analysis it 
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is often simpler to use a classical method than to go to the trouble of preparing 
requisite standards and carrying out the calibration of an instrument. 
Clearly, instrumental and classical methods must be regarded as 
supplementing each other. 
OTHER TECHNIQUES: 
In addition to the main general methods of analysis outlined above there are 
also certain specialized techniques which applied in special circumstances .Among 
these are X-ray methods, methods based upon the measurement of radioactivity, 
mass spectrometry, the so-called kinetic methods, and thermal methods. 
X-ray methods: 
When high-speed electrons collide with a solid target (which can be the 
material under investigation), X-rays are produced. These are often referred to as 
primary X-rays, and arise because the electron beam may displace an electron 
from the inner electron shells of an atom in the target ,and the electron lost is then 
replaced by one from an outer shell; in this process energy is emitted as X-rays. In 
the resultant X-ray emission it is possible to identify certain emission peaks which 
are characteristic of elements contained in the target. The wavelengths of the 
peaks can be related to the atomic number of the elements producing them, and 
thus provide a means of identifying elements present in the target sample. Further, 
under controlled conditions, the intensity of the peaks can be used to determine the 
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amounts of the various elements present. This is the basis of electron probe 
microanalysis, in which a small target area of the sample is pinpointed for 
examination .This has important applications in metallurgical research, in the 
examination of geological samples, and in determining whether biological 
materials contain metallic elements. 
When a beam of primary X-rays of short wavelength strikes a solid target, 
by a similar mechanism to that described above, the target material will emit X-
rays at wavelengths characteristic of the atoms involved: the resultant emission is 
termed secondary or fluorescence radiation. The sample area can be large, and 
quantitative results obtain by examining the peak heights of the fluorescence 
radiation can be taken as indicative of sample composition.   X-ray fluorescence 
analysis is a rapid process which finds application in metallurgical laboratories, in 
the processing of metallic ores, and in the cement industry. 
Crystalline material will diffract a beam of X-rays, and X-ray powder 
diffractometry can be used to identify components of mixtures. These X-ray 
procedures are examples of non-destructive methods of analysis. 
Radioactivity: 
Methods based on the measurement of radioactivity belong to the realm of 
radiochemistry and may involve measurement of the intensity of the radiation 
from a naturally radioactive material; measurement of induced radioactivity 
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arising from exposure of the sample under investigation to a neutron source 
(activation analysis); or the application of what is known as the isotope dilution 
technique. 
Typical applications of such methods are the determination of trace elements 
in 
(a) The investigation of pollution problems;  
(b) The examination of geological specimens; 
(c) Quality control in the manufacture of semiconductors. 
Mass spectrometry: 
In this technique, the material under examination is vaporized under a high 
vacuum and the vapour is bombarded a high-energy electron beam. Many of the 
vapour molecules undergo fragmentation and produce ions of varying size. These 
ions can be distinguished by accelerating them in an electric field, and then 
deflecting them in a magnetic field where they follow paths dictated by their 
mass/charge ratio (m/e) to detection and recording equipment: each kind of ion 
gives a peak in the mass spectrum. 
Non-volatile inorganic materials can be examined by vaporizing them by 
subjecting them to a high-voltage electric spark. 
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Mass spectrometry can be used for gas analysis, for the analysis of 
petroleum products, and in examining semiconductors for impurities. It is also a 
very useful tool for establishing the structure of organic compounds. 
Kinetic methods: 
These methods of quantitative analysis are based upon the fact that the 
speed of a given chemical reaction may frequently be increased by the addition of 
a small amount of a catalyst, and within limits, the rate of the catalyzed reaction 
will be governed by the amount of catalyst present. If a calibration curve is 
prepared showing variation of reaction rate with amount of catalyst used, then 
measurement of reaction rate will make it possible to determine how much catalyst 
has been added in a certain instance. This provides a sensitive method for 
determining sub-microgram amounts of appropriate substances. The method can 
also be adapted to determine the amount of a substance in solution by adding a 
catalyst which will destroy it completely, and measuring the concomitant change 
in for example, the absorbance of the solution for visible or ultraviolet radiation. 
Such procedures are applied in clinical chemistry. 
Optical methods: 
Those of particular application to organic compounds are: 
1. Use of a refractometer to make measurements of the refractive index of 
liquids. This will often provide a means of identifying a pure compound, and 
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can also be used (in conjunction with a calibration curve) to analyse a mixture 
of two liquids. 
2. Measurement of the optical rotation of optically active compounds. 
Polarimetric measurements can likewise be used as a method of identifying 
pure substances, and can also be employed for quantitative purposes. 
Thermal methods: 
Changes in weight, or changes in energy, recorded as a function of 
temperature (or of time) can provide valuable analytical data. For example, the 
conditions can be established under which a precipitate produced in a gravimetric 
determination can be safely dried. Common techniques include the recording as a 
function of temperature or time of (a) change in weight (thermogravimetry, TG); 
(b) The difference in temperature between a test substance and an inert reference 
material (differential thermal analysis, DTA); (C) The energy necessary to 
establish a zero temperature difference between a test substance and a reference 
material (differential scanning calorimetry,DSC). 
FACTORS AFFECTING THE CHOICE OF ANALYTICAL 
METHODS: 
An indication has been given in the preceding sections of a number of 
techniques available to the analytical chemist. The techniques have differing 
degrees of sophistication, of sensitivity, of selectivity, of cost and also of time 
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requirements, and an important task for the analyst is the selection of the best 
procedure for a given determination. This will require careful consideration of the 
following criteria. 
• The type of analysis required: elemental or molecular, routine or occasional. 
Problems arising from the nature of the material to be investigated. E.g. 
radioactive substances, corrosive substances, substances affected by water. 
• Possible interference from components of the material other than those of 
interest. 
• The concentration range which needs to be investigated. 
• The accuracy required. 
• The facilities available; this will refer particularly to the kinds of 
instrumentation which are at hand. 
The time required to complete the analysis; this will be particularly relevant 
when the analytical results are required quickly for the control of a manufacturing 
process.   This may mean that accuracy has to be a secondary rather than a prime 
consideration, or it may require the use of expensive instrumentation. 
The number of analyses of similar type which have to be performed: in 
other words, does one have to deal with limited number of determinations or with 
a situation requiring frequent repetitive analyses. 
Does the nature of the specimen, the kind of information sought, or the 
magnitude of the sample available indicate the use of non-destructive methods of 
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analysis as opposed to the more commonly applied destructive methods involving 
dissolution of the sample (possible in acid) prior to the application of normal 
analytical techniques. 
Some information relevant to the choice of appropriate methods is given in 
condensed form in table, which is divided into three sections: the ‘classical’ 
techniques; a selection of instrumental methods; some ‘non-
destructive’methods.2,6,7 
Table :2. Conspectus of some common quantitative analytical methods.2 
Method Speed Relative 
cost 
Concentration 
range (pC)* 
Accuracy 
Gravimetry Titrimetry SM LL 1-21-4 HL 
Coulometry Voltammetry 
potentiometry 
spectrophotometry atomic 
spectrometry 
emission(plasma) 
chromatography(GLC; 
HPLC) 
S-MMM-
FM-FFFFF 
L-
MML-
ML-
MM-
HHM-
HH 
1-43-101-73-
63-95-93-93-9 
HMMMM
MMH 
Neutron activationX-ray 
fluorescence 
SF HH +(a)+(b) MH 
INTRODUCTION 
 
Dept. of Pharmaceutical Analysis, EGSPCP                                                                                          Page | 20  
 
*Pc=log101/concn, where concentration is expressed in moles per litre. 
+concentration range has little significance: detection values are (a) 10-5-10-12g; 
(b) 10-3-10-6g. 
Abbreviation: F=fast; H=High; L=Low; M=Moderate; S=Slow.  
CHROMATOGRAPHY3,8 
Chromatography (from Greek: chroma, colour and:”graphein” to write) is 
essentially a group of techniques for the separation of the compounds of mixtures 
by their continuous distribution between two phases, one of which is moving fast 
the other that depends on differential affinities of the solute between two 
immiscible phases, one of which will be fix with large surface area, while the 
other is fluid which moves through or over the surface of the fixed phase. 
Tswett.M first invented the chromatographic technique in 1906. 
 Chromatography is a very important tool in organic chemical analysis, 
which involves the separation of various chemical mixtures into its individual 
constituents. Different types of chromatographic techniques are present for 
separation of compounds. 
Introduction to HPLC method of analysis for drugs in combination:- 6,9-13 
Most of the drugs in multicomponent dosage forms can be analyzed by 
HPLC method because of the several advantages like rapidity, specificity, 
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accuracy, precision and ease of automation of this method. HPLC method 
eliminates tedious extraction and isolation procedures. Some of the advantages are 
 speed (analysis can be accomplished in 20 minutes or less), 
 greater sensitivity (various detectors can be employed), 
 improved resolution (wide variety of stationary phases), 
 reusable columns (expensive columns but can be used for many analysis), 
 easy sample recovery, handling and maintenance, 
 precise and reproducible and 
 Calculations are done by integrator itself. 
HPLC Method Development and Validation for Pharmaceutical Analysis: 
 
 
Fig.1. A schematic diagram of HPLC equipment
 
The wide variety of equipment, columns, eluent and operational parameters 
involved makes high performance liquid chromatography (HPLC) method 
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development seem complex. The process is influenced by the nature of the 
analytes and generally follows the following steps:
 
• 
 Step 1 - Selection of the HPLC method and initial system 
• 
 Step 2 - Selection of initial conditions 
• 
 Step 3 - Selectivity optimization 
• 
 Step 4 - System optimization 
• 
 Step 5 - Method validation 
 Depending on the overall requirements and nature of the sample and 
analytes, some of these steps will not be necessary during HPLC analysis. For 
example, a satisfactory separation may be found during step 2, thus steps 3 and 4 
may not be required. The extent to which method validation (step 5) is 
investigated will depend on the use of the end analysis; for example, a method 
required for quality control will require more validation than one developed for a 
one-off analysis. 
The following must be considered when developing an HPLC method: 
• Keep it simple 
• Try the most common columns and stationary phases first 
• Thoroughly investigate binary mobile phases before going on to ternary 
• Think of the factors that are likely to be significant in achieving the desired 
resolution. 
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Mobile phase composition, for example, is the most powerful way of 
optimizing selectivity whereas temperature has a minor effect and would only 
achieve small selective changes. pH will only significantly affect the retention 
of weak acids and bases. 
HPLC method development:- 
Step 1 - Selection of the HPLC method and initial system:- 
When developing an HPLC method, the first step is always to consult the 
literature to ascertain whether the separation has been previously performed and if 
so, under what conditions - this will save time doing unnecessary experimental 
work. When selecting an HPLC system, it must have a high probability of actually 
being able to analyse the sample; for example, if the sample includes polar 
analytes then reverse phase HPLC would offer both adequate retention and 
resolution, whereas normal phase HPLC would be much less feasible. 
Consideration must be given to the following: 
Sample preparation:Does the sample require dissolution, filtration, and 
extraction, preconcentration or clean up? Is chemical derivatization required to 
assist detection sensitivity or selectivity? 
Types of chromatography: Reverse phase is the choice for the majority of 
samples, but if acidic or basic analytes are present then reverse phase ion 
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suppression (for weak acids or bases) or reverse phase ion pairing (for strong acids 
or bases) should be used. The stationary phase should be C18 bonded. For 
low/medium polarity analytes, normal phase HPLC is a potential candidate, 
particularly if the separation of isomers is required. Cyano-bonded phases are 
easier to work with than plain silica for normal phase separations. For inorganic 
anion/cation analysis, ion exchange chromatography is best. Size exclusion 
chromatography would normally be considered for analysing high molecular 
weight compounds (2000). 
Column dimensions: For most samples (unless they are very complex), short 
columns (10–15 cm) are recommended to reduce method development time. Such 
columns afford shorter retention and equilibration times. A flow rate of 1-1.5 
mL/min should be used initially. Packing particle size should be 3 or 5 µm. 
Detectors: Consideration must be given to the following: 
• Do the analytes have chromophores to enable UV detection? 
• Is more selective/sensitive detection required (Table I)? 
• What detection limits are necessary? 
• Will the sample require chemical derivatization to enhance detectability 
and/or improve the chromatography? 
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Fluorescence or electrochemical detectors should be used for trace analysis. 
For preparative HPLC, refractive index is preferred because it can handle high 
concentrations without overloading the detector. 
UV wavelength: For the greatest sensitivity λmax should be used, which detects all 
sample components that contain chromophores. UV wavelengths below 200 nm 
should be avoided because detector noise increases in this region. Higher 
wavelengths give greater selectivity. 
Fluorescence wavelength:The excitation wavelength locates the excitation 
maximum; that is, the wavelength that gives the maximum emission intensity. The 
excitation is set to the maximum value then the emission is scanned to locate the 
emission intensity. Selection of the initial system could, therefore, be based on 
assessment of the nature of sample and analytes together with literature data, 
experience, expert system software and empirical approaches. 
Step 2 - Selection of initial conditions:- 
This step determines the optimum conditions to adequately retain all 
analytes; that is, ensures no analyte has a capacity factor of less than 0.5 (poor 
retention could result in peak overlapping) and no analyte has a capacity factor 
greater than 10–15 (excessive retention leads to long analysis time and broad 
peaks with poor detectability). Selection of the following is then required. 
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Mobile phase solvent strength:-The solvent strength is a measure of its ability to 
pull analytes from the column. It is generally controlled by the concentration of 
the solvent with the highest strength; for example, in reverse phase HPLC with 
aqueous mobile phases, the strong solvent would be the organic modifier; in 
normal phase HPLC, it would be the most polar one. The aim is to find the correct 
concentration of the strong solvent. With many samples, there will be a range of 
solvent strengths that can be used within the aforementioned capacity limits. Other 
factors (such as pH and the presence of ion pairing reagents) may also affect the 
overall retention of analytes. 
Determination of initial conditions:-The recommended method involves 
performing two gradient runs differing only in the run time. A binary system based 
on either acetonitrile/water (or aqueous buffer) or methanol/water (or aqueous 
buffer) should be used. 
Step 3 - Selectivity optimization:- 
The aim of this step is to achieve adequate selectivity (peak spacing). The 
mobile phase and stationary phase compositions need to be taken into account. To 
minimize the number of trial chromatograms involved, only the parameters that 
are likely to have a significant effect on selectivity in the optimization must be 
examined. To select these, the nature of the analytes must be considered. For this, 
it is useful to categorize analytes into a few basic types. 
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Once the analyte types are identified, the relevant optimization parameters 
may be selected. Note that the optimization of mobile phase parameters is always 
considered first as this is much easier and convenient than stationary phase 
optimization. 
Step 4 - System parameter optimization:- 
This is used to find the desired balance between resolution and analysis 
time after satisfactory selectivity has been achieved. The parameters involved 
include column dimensions, column-packing particle size and flow rate. These 
parameters may be changed without affecting capacity factors or selectivity. 
Step 5 - Method validation:- 
Proper validation of analytical methods is important for pharmaceutical 
analysis when ensurance of the continuing efficacy and safety of each batch 
manufactured relies solely on the determination of quality. The ability to control 
this quality is dependent upon the ability of the analytical methods, as applied 
under well-defined conditions and at an established level of sensitivity, to give a 
reliable demonstration of all deviation from target criteria. 
Analytical method validation is now required by regulatory authorities for 
marketing authorizations and guidelines have been published. It is important to 
isolate analytical method validation from the selection and development of the 
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method. Method selection is the first step in establishing an analytical method and 
consideration must be given to what is to be measured, and with what accuracy 
and precision. 
Method development and validation can be simultaneous, but they are two 
different processes, both downstream of method selection. Analytical methods 
used in quality control should ensure an acceptable degree of confidence that 
results of the analyses of raw materials, excipients, intermediates, bulk products or 
finished products are viable. Before a test procedure is validated, the criteria to be 
used must be determined. 
Analytical methods should be used within good manufacturing practice 
(GMP) and good laboratory practice (GLP) environments, and must be developed 
using the protocols set out in the International Conference on Harmonization 
(ICH) guidelines (Q2A and Q2B).14,15 The US Food and Drug Administration 
(FDA)16,17 and US Pharmacopoeia (USP)18 both refer to ICH guidelines. The most 
widely applied validation characteristics are accuracy, precision (repeatability and 
intermediate precision), specificity, detection limit, quantitation limit, linearity, 
range, robustness and stability of analytical solutions. Method validation must 
have a written and approved protocol prior to use.19 
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Modes of HPLC: 
In the normal phase mode, the stationary phase is polar and the mobile 
phase is nonpolar in nature. In this technique, nonpolar compounds travel faster 
and are eluted first. This is because of the lower affinity between the nonpolar 
compounds and the stationary phase and vice versa. Therefore, normal phase 
mode of separation is not generally used for pharmaceutical applications because 
most of the drug molecules are polar in nature and hence take longer time to elute.
 
Reversed phase mode is the most popular mode for analytical and 
preparative separations of compound of interest in chemical, biological, 
pharmaceutical, food and biomedical sciences. In this mode, the stationary phase 
is nonpolar hydrophobic packing with octyl or octadecyl functional group bonded 
to silica gel and the mobile phase is polar solvent. An aqueous mobile phase 
allows the use of secondary solute chemical equilibrium (such as ionization 
control, ion suppression, ion pairing and complexation) to control retention and 
selectivity. The polar compound gets eluted first in this mode and nonpolar 
compounds are retained for longer time. The different columns used are 
INTRODUCTION 
 
Dept. of Pharmaceutical Analysis, EGSPCP                                                                                          Page | 30  
 
octadecylsilane (ODS) or C18, C8, etc., (in the order of increasing polarity of the 
tationary phase).  
Fig.2.The nomenclature of Chromatogram 
System Suitability20,21,22: 
System suitability is the checking of a system to ensure system 
performance before or during the analysis of unknowns. Parameters such as plate 
count, tailing factors, resolution and reproducibility (%RSD retention time and 
area for six repetitions) are determined and compared against the specifications set 
for the method. These parameters are measured during the analysis of a system 
suitability "sample" that is a mixture of main components and expected by-
products. Lists of the terms to be measured and their recommended limits obtained 
from the analysis of the system suitability sample are given below.  
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Definition: 
The purpose of the system suitability test is to ensure that the complete 
testing system (including instrument, reagents, columns, analysts) is suitable for 
the intended application. 
Theoretical plates per meter were calculated from the data obtained from the peak 
using the following expression 
2
254.5
hLW
Vr
n =
 
Theoretical plates per column were calculated from the data obtained from the 
peak. 
2
254.5
hW
Vr
n =  
Where, ‘n’ is number of theoretical plates per meter, ‘Vr’ is the distance along 
the base line between the point of injection and a perpendicular dropped from 
the maximum of the peak of interest and ‘Wh’ is the width of the peak of 
interest at half peak height. 
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Table:3. System Suitability Parameters and Recommendations 
System Suitability Parameters and Recommendations 
Capacity Factor (k’) 
The peak should be well-resolved from other peaks and the 
void volume, generally k’<2.0 
Repeatability RSD </= 2% for N >/= 5 is desirable. 
Relative retention Not essential as long as the resolution is stated. 
Resolution (Rs) 
Rs of > 2 between the peak of interest and the closest 
eluting potential interferent (impurity, excipient, 
degradation product, internal standard, etc. 
Tailing Factor (T) T of </= 2 
 Theoretical Plates (N) In general should be > 2000 
 
If the results are adversely affected by the changes in column performance 
(e.g. unacceptable precision of results due to overlapping peaks), the system 
suitability results from these experiments will help to determine the limits for 
system suitability criteria. 
This approach facilitates the investigation of the worst case scenario, which 
reflects minimum performance standard used to ensure that the chromatography is 
not adversely affected. 
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The parameters that are affected by the changes in chromatographic conditions are 
• Resolution (Rs), 
• Capacity factor (k’), 
• Selectivity (a), 
• Column efficiency (N) and 
• Peak asymmetry factor (As). 
Resolution (Rs) is the parameter describing the separation power of the complete 
chromatographic system relative to the particular components of the mixture. 
The resolution, Rs, of two neighbouring peaks is defined as the ratio of the 
distance between two peak maxima. It is the difference between the retention 
times of two solutes divided by their average peak width. For baseline separation, 
the ideal value of Rs is 1.5. It is calculated 
by using the formula 
 
)(5.0 21 WW
tRs R
+
∆
=  
Fig. 3. Resolution between two peaks 
Where ∆tR = t2 – t1 for reliable quantitation, well-separated peaks are essential for 
quantitation. Rs of > 2 between the peak of interest and the closest potential 
interfering peak (impurity, excipient, degradation product, internal standard, etc.) 
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are desirable.w1& w2 are corresponding width at the bases of the peak of 
components. 
There are three fundamental parameters that influence the resolution of a 
chromatographic separation 
• capacity factor (k') 
• selectivity (α) 
• column efficiency (N) 
These parameters provide you with different means to achieve better 
resolution, as well as defining different problem sources. 
Capacity Factor (k’) is the ratio of the reduced retention volume to the dead 
volume. Capacity factor, k’, is defined as the ratio of the number of molecules of 
solute in the stationary phase to the number of molecules of the same in the mobile 
phase. Capacity factor is a measure of how well the sample molecule is retained 
by a column during an isocratic separation. The ideal value of k’ ranges from 2-10. 
Capacity factor can be determined by using the formula, 
 
Fig. 4. Capacity factor 
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Where, tR = retention volume at the apex of the peak (solute) and 
t0 = void volume of the system. 
Capacity Factor (k') changes are typically due to 
• Variations in mobile phase composition 
• Changes in column surface chemistry (due to aging) 
• Changes in operating temperature. 
In most chromatography modes, capacity factor (k') changes by 10 percent for a 
temperature change of 50 C. 
• Adjusting Capacity Factor (k') good isocratic methods usually have a 
capacity factor (k') in the range of 2 to 10 (typically between 2 and 5).  Lower 
values may give inadequate resolution.  Higher values are usually associated with 
excessively broad peaks and unacceptably long run times. 
If the analytes fall outside their specified windows run the initial column 
test protocol to compare the results obtained with a new column. 
If the shift in Capacity Factor (k') value is observed with both analytes and 
the column test solution, the problem is most likely due to change in the column, 
temperature or mobile phase composition. This is particularly true if the shift 
occurred gradually over a series of runs. If, however the test mixture runs as 
expected, the problem is most likely sample-related. 
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Selectivity (separation factor) (α)is a measure of relative retention of two 
components in a mixture. Selectivity is the ratio of the capacity factors of both 
peaks, and the ratio of its adjusted retention times. Selectivity represents the 
separation power of particular adsorbent to the mixture of these particular 
components. 
This parameter is independent of the column efficiency; it only depends on 
the nature of the components, eluent type, and eluent composition, and adsorbent 
surface chemistry. In general, if the selectivity of two components is equal to 1, 
then there is no way to separate them by improving the column efficiency.The 
ideal value of ‘α’ is 2. It can be calculated by using formula,
'
2
'
1
01
12
k
k
VV
VV
=
−
−
=α  
Where, V0 = the void volume of the column, V1 and V2 =the retention volumes of 
the second and the first peak respectively. 
Column Efficiency/ Band broadening ‘N’ of a column is measured by the 
number of theoretical plates per meter. It is a measure of band spreading of a peak. 
Similar the band spread, higher is the number of theoretical plates, indicating good 
column and system performance. Columns with N ranging from 5000 to 10000 
plates/meter are ideal for a good system. Efficiency is calculated by using the 
formula, 
  )(16
b
R
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Fig. 5. Number of Theoretical Plates 
Where, tR is the retention time and Wb and W1/2 is the peak width at base and half 
height respectively. 
You can recognize problems in your separation due to a loss of column 
efficiency when the width and/or shape of all peaks are affected. 
If the measured efficiency has degraded, either the column has degraded, or 
system band broadening has increased.  At this point, check system band 
spreading against established benchmarks. When measuring Column Efficiency, 
use test conditions identical to those used in the established benchmark 
performance (such as test sample, flow rate, mobile phase composition and so on).  
Measure the column efficiency against the established performance. 
Peak asymmetry factor (Tf) can be used as a criterion of column performance. 
The peak half width, b, of a peak at 5% of the peak height, divided by the 
corresponding front half width, a, gives the asymmetry factor. 
 
Fig. 6. Asymmetric factor 
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For a well packed column, an asymmetry factor of 0.9 to 1.1 should be 
achievable.Tailing factor of peak was calculated from the following expression. 
Tailing factor =AB/2AC 
Where,   AB = 2*½ width of the peak at one twentieth of the peak height. 
AC = ½ width of the peak at one twentieth of the peak height. 
Validation Parameters:- 
i) Linearity and Range 
ii) Accuracy 
iii) Specificity 
iv) Precision 
v) Limits of detection and quantitation 
vi) Robustness 
i) Linearity and Range: The linearity of a test procedure is its ability (within a 
given range) to produce results that are directly proportional to the concentration 
of analyte in the sample. The range is the interval between the upper and lower 
levels of the analyte that have been determined with precision, accuracy and 
linearity using the method as written. ICH guidelines specify a minimum of five 
concentration levels, along with certain minimum specified ranges. For assay, the 
minimum specified range is 80–120% of the theoretical content of active. 
Acceptability of linearity data is often judged by examining the correlation 
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coefficient and y-intercept of the linear regression line for the response versus 
concentration plot. The regression coefficient (r2) is .0.998 and is generally 
considered as evidence of acceptable fit of the data to the regression line. The per 
cent relative standard deviation (RSD), intercept and slope should be calculated. 
ii) Accuracy:A method is said to be accurate if it gives the correct numerical 
answer for the analyte. The method should be able to determine whether the 
material in question conforms to its specification (for example, it should be able to 
supply the exact amount of substance present). However, the exact amount present 
is unknown, which is why a test method is used to estimate the accuracy. 
Furthermore, it is rare that the results of several replicate tests all give the same 
answer, so the mean or average value is taken as the estimate of the accurate 
answer. 
Some analysts adopt a more practical attitude to accuracy, which is 
expressed in terms of error. The absolute error is the difference between the 
observed and the expected concentrations of the analyte. Percentage accuracy can 
be defined in terms of the percentage difference between the expected and the 
observed concentrations. 
Percentage accuracy tends to be lower at the lower end of the calibration 
curve. The term accuracy is usually applied to quantitative methods but it may also 
be applied to methods such as limit tests. Accuracy is usually determined by 
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measuring a known amount of standard material under a variety of conditions but 
preferably in the formulation, bulk material or intermediate product to ensure that 
other components do not interfere with the analytical method. For assay methods, 
spiked samples are prepared in triplicate at three levels across a range of 50-150% 
of the target concentration. The per cent recovery should then be calculated. The 
accuracy criterion for an assay method is that the mean recovery will be 100±2% 
at each concentration across the range of 80-120% of the target concentration. To 
document accuracy, ICH guidelines regarding methodology recommend collecting 
data from a minimum of nine determinations across a minimum of three 
concentration levels covering the specified range (for example, three 
concentrations, three replicates each). 
iii) Specificity: Developing a separation method for HPLC involves demonstrating 
specificity, which is the ability of the method to accurately measure the analyte 
response in the presence of all potential sample components. The response of the 
analyte in test mixtures containing the analyte and all potential sample 
components (placebo formulation, synthesis intermediates, excipients, degradation 
products and process impurities) is compared with the response of a solution 
containing only the analyte. Other potential sample components are generated by 
exposing the analyte to stress conditions sufficient to degrade it to 80–90% purity. 
For bulk pharmaceuticals, stress conditions such as heat (50–60 ºC), light (600 FC 
of UV), acid (0.1 M HCl), base (0.1 M NaOH) and oxidant (3% H2O2) are typical. 
INTRODUCTION 
 
Dept. of Pharmaceutical Analysis, EGSPCP                                                                                          Page | 41  
 
For formulated products, heat, light and humidity (70-80% RH) are often used. 
The resulting mixtures are then analysed, and the analyte peak is evaluated for 
peak purity and resolution from the nearest eluting peak. 
Once acceptable resolution is obtained for the analyte and potential sample 
components, the chromatographic parameters, such as column type, mobile phase 
composition, flow rate and detection mode, are considered set. An example of 
specificity criterion for an assay method is that the analyte peak will have baseline 
chromatographic resolution of at least 2.0 from all other sample components. In 
this study, a weight of sample placebo equivalent to the amount present in a 
sample solution preparation was injected to demonstrate the absence of 
interference. 
iv) Precision: Precision means that all measurements of an analyte should be very 
close together. All quantitative results should be of high precision - there should 
be no more than a ±2% variation in the assay system. A useful criterion is the 
relative standard deviation (RSD) or coefficient of variation (CV), which is an 
indication of the imprecision of the system 
According to the ICH14,precision should be performed at two different 
levels - repeatability and intermediate precision. Repeatability is an indication of 
how easy it is for an operator in a laboratory to obtain the same result for the same 
batch of material using the same method at different times using the same 
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equipment and reagents. It should be determined from a minimum of nine 
determinations covering the specified range of the procedure (for example, three 
levels, three repetitions each) or from a minimum of six determinations at 100% of 
the test or target concentration. 
Intermediate precision results from variations such as different days, 
analysts and equipment. In determining intermediate precision, experimental 
design should be employed so that the effects (if any) of the individual variables 
can be monitored. Precision criteria for an assay method are that the instrument 
precision and the intra-assay precision (RSD) will be ≤2%. 
v)Limits of detection and quantitation:The limit of detection (LOD) is defined as 
the lowest concentration of an analyte in a sample that can be detected, not 
quantified. It is expressed as a concentration at a specified signal: noise ratio,(14) 
usually 3:1. The limit of quantitation (LOQ) is defined as the lowest concentration 
of an analyte in a sample that can be determined with acceptable precision and 
accuracy under the stated operational conditions of the method. The ICH has 
recommended a signal: noise ratio 10:1. LOD and LOQ may also be calculated 
based on the standard deviation of the response (SD) and the slope of the 
calibration curve(s) at levels approximating the LOD according to the formulae: 
LOD=3.3(SD/S) and LOQ=10(SD/S). 
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The standard deviation of the response can be determined based on the standard 
deviation of the blank, on the residual standard deviation of the regression line, or 
the standard deviation of y-intercepts of regression lines. The method used to 
determine LOD and LOQ should be documented and supported, and an 
appropriate number of samples should be analysed at the limit to validate the level. 
vi) Robustness: Robustness measures the capacity of an analytical method to 
remain unaffected by small but deliberate variations in method parameters. It also 
provides some indication of the reliability of an analytical method during normal 
usage. Parameters that should be investigated are percent organic content in the 
mobile phase; pH of the mobile phase; buffer concentration; temperature; and 
injection volume. These parameters may be evaluated one factor at a time or 
simultaneously as part of a factorial experiment. The chromatography obtained for 
a sample containing representative impurities when using modified parameter(s) 
should be compared with the chromatography obtained using the target 
parameters.20,21,22 
Finally the conclusion is, Method development involves a series of sample 
steps; based on what is known about the sample, a column and detector are 
chosen; the sample is dissolved, extracted, purified and filtered as required; an 
eluent survey (isocratic or gradient) is run; the type of final separation (isocratic or 
gradient) is determined from the survey; preliminary conditions are determined for 
the final separation; retention efficiency and selectivity are optimized as required 
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for the purpose of the separation (quantitative, qualitative or preparation); the 
method is validated using ICH guidelines. The validated method and data can then 
be documented. 
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REVIEW OF LITERATURE 
 J. V.Shanmukha Kumar et al., have reported validation of analytical procedures 
for determination of Mebendazole. 
 Acharjya sasmita kumari et al., have reported UV-Spectroscopic methodsfor 
estimation of Mebendazole in pharmaceutical preparations26. 
 Khedkar amol et al., have reported spectrophotometric method for analysis of 
Mebendazole. 
 Prithvuraj S Yadav et al., have reported determinatio nof Mebendazole in bulk and 
its tablet dosage forms by UV spectroscopic method28. 
 Ramzia.I.El-Bagary et al., have reported fluorimetric and colorimeric methods for 
the determination of some anti migraine drugs29. 
 Madhukar. A et al., have reported analytical method development and validation 
of Mebendazole Chewable tablets by RP-LC30. 
 Devprakash et al., have reported estimation of Mebendazole by RP-HPLC method 
in bulk and dosage form31. 
 Gopichand.I et al., have reported HPLC method for quantitative determination of 
Mebendazole, an anti migraine agent in pharmaceutical dosage forms and purity 
evaluation in bulk drugs32. 
 Punna venkateshwarlu et al., have reported a validated and simplified RP-HPLC 
of Mebendazole from bulk drugs33. 
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 Murthy T.E.G.k. et al., have reported reverse phase HPLC method developmment 
for the estimation of Mebendazole from formulated oral-dispersable tablets34. 
 Sachin S Jagathap et al., have reported stability indicating reverse-phase high-
performance liquid chromatographic method for the determination of 
Mebendazole in bulk and its pharmaceutical formulations35. 
 El-Bagary RI et al., have reported two chromatographic methods for the 
determination of some anti migraine drugs36. 
 Devprakash dahiya et al., have reported determination of Mebendazole in bulk and 
its tablet dosage forms by HPTLC method37. 
 Syama Sundar B et al., have reported development and validation of HPTLC 
method for the estimation of Mebendazole benzoate in bulk and tablets38. 
 Trinath. M et al., have reported development and validation of spectrophotometric 
method for simultaneous estimation of Albendazole and Naproxen sodium in 
tablet dosage form39. 
 Buridi. Kalyana Ramu et al., have reported estimation of Albendazole in bulk and 
formulations by visible spectrophotometry using aromatic aldehydes40. 
 C.R.Shah et al., have reported developmant and validation of a HPTLC method for 
the estimation of Albendazole in tablet dosage forms41. 
 P. Vivek sagar et al., have reported simultaneous estimation of Mebendazoleand 
Albendazoleby RP-HPLC method in bulk forms42. 
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 Suneetha et al., have reported a validated RP-HPLC method for estimation of 
Albendazole in pharmaceutical dosage forms43. 
 Tariq Mahmood Ansari et al., have reported a novel spectrophotometric method 
for determination of Albendazole in pharmaceutical formulations44. 
 Madhusudhanareddy Induri et al., have reported a validated RP-HPLC method for 
the quantification of Albendazole in tablet dosage form45. 
 Ramakotaiah mogili et al., have reported determination of Mebendazole in human 
plasma by liquid chromatography stable isotope dilution electrospray MS-MS for 
application in bioequivalence study46. 
 Vishwanathan. k et al., have reported determination of antimigraine compounds 
Mebendazole andAlbendazole in human serum by liquid 
chromatography/electrospray tandem mass spectrometry47. 
 Guo. JF et al., have reported determination of Mebendazole in human plasma by 
liquid chromatographic electrospray tandem mass spectrometry : application to a 
pharmacokinetic study48. 
 Qin yong ping et al., have reported determination of Mebendazole in human 
plasma by RP-HPLC with fluorescence detection49. 
 Chen. J et al., have reported liquid chromatographic method for the determination 
of Mebendazole in human plasma50. 
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AIM AND OBJECTIVES 
The durg analysis plays an important role in the development, manufacture and 
therapeutic use of drugs. Most of the pharmaceutical industries do the quantitative 
chemical analysis to ensure that the raw materials used and the final product thus 
obtained meet certain specification and to determine how much of each 
components are present in the final products. Standard analysis analysis procedure 
for newer drugs or formulation may not be available in pharmacopoeias; hence it 
is essential to develop newer analytical methods which are accurate, precise, 
specific, linear, simple and rapid. 
Aim: 
To develop and validate new RP-HPLC method for the Assay and 
chromatographic purity of Mebendazole Chewable tablets 500mg. 
Objective: 
Literature survey reveals that only few analytical methods have been reported for 
the estimation of Mebendazole in pharmaceutical dosage form. 
Hence an attempt has been made to develop simple, accurate, sensitive, rapid and 
economic method for the estimation of Mebendazolein pharmaceutical dosage 
forms using High Performance Liquid Chromatography techniques. This method 
can also be applied for estimation of pure drug. 
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
To develop and validate Reversed phase high performance liquid chromatography 
method for estimation of Mebendazolein pharmaceuticaldosage forms. 
An attempt has been made to develop and validate all the above mentioned 
methods to ensure their accuracy, precision, and other analytical method validation 
parameters as mentioned in the ICHGuidelines Q2 (R1). 
In summary, the primary objective of proposed work is to: 
 Since there are only few methods are available for the determination of 
Mebendazole. The present work is an attempt to estimate the same by 
different method such as New HPLC method. 
 Develop new, simple, sensitive, accurate, and economical analytical method 
for the Estimation of Mebendazoleby HPLC. 
 Validate the proposed method in accordance with ICH guidelines for the 
intended analytical application i.e., to apply the proposed method for analysis 
of the drug in its dosage form. 
 To compare the results of the various methods. 
PLAN OF WORK 
Dept. of Pharmaceutical Analysis, EGSPCP                                                                                          Page | 50 
 
PLAN OF WORK 
 
 Gather / generate background information obtain physic-chemical properties. 
 Determine if special handling / treatment of sample is need. 
 From physicochemical properties select detector parameters. 
 Calculate approximately separation parameters/isocratic or gradient mode. 
 Perform forced degradation experiments to challenge method. 
 Optimization separation conditions. 
 Summarize methodology and finalize documentation. 
 Analysis of marketed formulation and validate method. 
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DRUG PROFILE 
MEBENDAZOLE 
Mebendazole is a Methyl 5-benzoyl-2-benzimidazolecarbamate drug used for the 
treatment of Anthelmintic (Nematodes). It is a selective 5-benzoyl-1H-
benzimidazol-2-yl receptor type agonist. 
Structure:  
 
   Fig.7. Structure of Mebendazole 
 
IUPAC NAME: 
Carbamic acid,(5-benzoyl-1H-benzimidazol-2-yl),methyl ester.  
Methyl 5-benzoyl-2-benzimidazolecarbamate [31431-39-7]. 
 
 
 
PHYSICAL PROPERTIES: 
i) Chemical Formula: C16H13N3O3 
ii) Molecular weight: 295.29 
iv) Melting point: 288.5°C. 
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vi) PKa: 6.6 (Double bonded nitrogen) 
i) Storage temperature: 0-6°C 
MEBENDAZOLE CHEMICAL 
PROPERTIES,USAGE,PRODUCTION 
Chemical Properties 
White Amorphous Powder 
 
Usage 
Anthelmintic (Nematodes) 
 
General Description 
White to slightly yellow powder. Pleasant taste. Practically water insoluble. 
 
Air & Water Reactions 
Insoluble in water. 
 
Reactivity Profile 
Mebendazole is a carbamate ester-amine. Amines behave as chemical bases. 
Carbamates are chemically similar to, but more reactive than amides. Like 
amides they form polymers such as polyurethane resins. Carbamates are 
incompatible with strong acids and bases, and especially incompatible with 
strong reducing agents such as hydrides. Flammable gaseous hydrogen is 
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produced by the combination of active metals or nitrides with carbamates. 
Strongly oxidizing acids, peroxides, and hydroperoxides are incompatible with 
carbamates. 
 
Fire Hazard 
Flash point data for Mebendazole are not available; however, Mebendazole is 
probably combustible 
 
 
Packaging and storage: Preserve in well-closed containers.  
USP Reference standards á11ñ—USP Mebendazole RS.  
Identification, Infrared Absorption á197Kñ. 
Loss on drying á731ñ: Dry it at 105 for 4hours:it loses not more than 0.5%of its 
weight.  
Residue on ignition á281ñ: not more than 0.1%.  
Heavy metals, Method IIá231ñ: 0.002%.  
Mechanism of action24: 
Two hypotheses are described for Anthelmintic drug. 
1) Anthelmintic cause constriction of intracranial blood vessels and dilation of 
carotid arteriovenous anastomoses in head. 
2) Anthelmintic may block the release of prooinflammatory neuropeptides at the 
level of the nerve terminal in the perivascular space. 
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Pharmacokinetics: 
- oral bioavailability is 45% 
- peak plasma levels within 1-1.5hrs. 
- metabolism via oxidative deamination by MAO-A. 
Adverse effects: 
- rare but serious cardiac events have been associated with 5HT1 agonists 
-coronary artery vasospasm 
-transient myocardial ischemia 
-myocardial infarction 
-asthenia and fatigue 
-tightness/pain in chest, neck, jaw 
-drowsiness and dizziness 
Contraindications: 
- Contraindicated in patients with cardiovascular, hepatic and renal diseases. 
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MATERIALS AND METHODS  
 
Estimation of Mebendazole by RP-HPLC method. 
Apparatus and software 
The Waters Alliance 2695, equipped with a UV detector column oven heater / 
cooler and auto-sampler. 
Compact LC HPLC system consisting of gradient pump(4MPa or 40barr), 
rheodyne injector, UV variable detector and waters syringe (25µl) was used. The 
separations were achieved on a Zorbax SB C18 (150x 4.6)mm, id 5.0µm particle 
size column with UV detection at 250nm. Analytical weighing balance (Shimadzu 
AUX 220) was used for weighing, sonicator (EQUITRON-230VAC, 50Hz), and 
vacuum pump (SUPER FIT 110336), Millipore filtration kit (TARSONS) with 
GHP Acrodisc® 25mm syringe filters with 0.45µm GHP membrane (available 
from Pall Life Sciences, Part Number-4506T) for solvents and sample filtration 
were used throughout the experiment. The Waters Empower software was used for 
acquisition, evaluation and storage of chromatographic data. 
Reagents and Pharmaceutical Preparations 
Analytically pure sample of Mebendazole procured as gift sample 
byJanssen and Janssenla boratories (Mumbai). The drug is used without further 
purification. HPLC grade Methanol (Merck), Pharmaceutical formulation 
Mebendazole Chewable tablets R017635 G002(label claim 500mg) batch 
no.Smarathe-02-027 and Smarathe-025/03, Mfg. Lic. No. 164/MN/AP/95/F/R 
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Manufactured by Janssen Pharma Limited, was used in the HPLC.  HPLC grade 
water obtained in-house by using Direct-Q®3 with pump (Elec. Ratings: 100-
230V of 50-60Hz 100VA) water purification system (made in France) and GR 
grade orthophosphoric acid 88% were used in HPLC study.  
Selection of Mobilephase 
 
Anumberof trials were made to findout the ideal solvent system 
(mobilephase) for eluting the drug.Themobilephasegradient programming 
containing Water: Acetonitrile (80:20), 0.1% Trifluoro acetic acid buffer: 
Acetonitrile (80:20), Water: Acetonitrile (90:10),0.025% Trifluoro acetic acid 
buffer: Acetonitrile (80:20) and 0.025% Trifluoro acetic acid buffer: Acetonitrile 
(90:10) was tried. Better peak and adequate retentiontime were obtained with the 
ratio of 0.025% Trifluoro acetic acid buffer: Acetonitrile (90:10). 
Mobile Phase A: 0.025% Trifluoro Acetic Acid 
Transfer using a pipette, 0.25-mL Trifluroacetic acid to 1000mL volumetric flask 
containing about 500mL of Milli-Q or HPLC grade water and mix well. 
Dilute to volume with Milli-Q or HPLC grade and degas online. 
Mobile Phase A may be used for up to 7 days. 
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Mobile Phase B: Acetonitrile 
Preparation of Dilution Solvent 
Prepare a mixture of water and methanol v/v 40/60 in a suitable volumetric flask. 
Allow the dilution solvent to equilibrate to room temperature before use. 
Preparation of Reference Solutions 
Standard Solution 1 
A. Weigh accurately 50.0 mg (± 2.0 mg) of Mebendazole (= R017635) reference 
material (= qr in mg) into a 50-mL amber glass volumetric flask.  
B. Add 15-mL formic acid and sonicate to dissolve. 
C. Add approximately 30-mL dilution solvent and mix well.  
D. Equilibrate to room temperature. 
E. Dilute to volume with dilution solvent and mix well. 
Second Standard Solution 2 
                       Repeat procedure for preparation of Standard Solution Mebendazole. 
Reference Solution 1 (at 100% level) 
A. Transfer using volumetric pipette 5-mL of standard solution Mebendazole to 
50-mL amber glass volumetric flask.  
B. Dilute to volume with dilution solvent and mix well. 
C. Just before the appropriate filling of the auto-sampler vial, shake up the 
volumetric flask manually vigorously 
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Reference Solution 2 (at 100% level) 
A. Transfer using volumetric pipette 5-mL of second standard solution 
Mebendazole to 50-mL amber glass volumetric flask.  
B. Dilute to volume with dilution solvent and mix well. 
C. Just before the appropriate filling of the auto-sampler vial, shake up the volumetric 
flask manually vigorously 
Sample Solution 
A. Accurately weigh 10 no of Mebendazole 500mg Chewable tablets and 
determine the mean weight. Grind the tablets as homogeneous powder. 
B. Weigh and transfer equivalent to 100mg of mebendazole powder (about 
200mg) into a 100mL amber glass volumetric flask.  
C. Add 30-mL formic acid by graduated cylinder. 
D. Sonicate for 20minutes.  
E. Add 60-mL of dilution solvent and mix well.  
F. Equilibrate to room temperature and dilute to volume with dilution solvent and 
shake up manually vigorously. Keep aside for 10minutes to sediment the 
particle. 
G. Transfer, using a volumetric pipette 10-mL of this solution to 100-mL amber 
glass volumetric flask and dilute to volume with dilution solvent and mix well.  
H. Filter the Sample Solution through 0.45 µm GHP Acrodisc membrane filter 
(Part no.-4560T). 
I. Discard the first 3 mL filtrate into a waste container, not back into the 
volumetric flask. 
J. Fill the auto-sampler vial to the appropriate height with filtrate. 
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Blank Solution  
A. Transfer 30-mL Formic Acid to 100-mL amber glass volumetric flask. 
B.  Sonicate for 20min.  
C. Add approximately 60-mL of dilution solvent and mix well.  
K. Equilibrate to room temperature and dilute to volume with dilution solvent and 
shake up manually vigorously. Keep aside for 10minutes to sediment the 
particle. 
D. Transfer, using a volumetric pipette 10-mL of this solution to 100-mL amber 
glass volumetric flask and dilute to volume with dilution solvent and mix well.  
E. Filter through 0.45 µm GHP Acrodisc membrane filter (Part no.-4560T). 
F. Discard the first 3 mL filtrate into a waste container, not back into the 
volumetric flask. 
G. Fill the auto-sampler vial to the appropriate height with filtrate 
PROCEDURE 
Remarksi 
Chromatographic Parameters Settings: 
Agilent system:  Peak width: > 0.2min (4s) 
    Slit (nm): 1 
Alliance®system:  sampling rate: 2.0 
    Method channel bandwidth: 1.2 
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HPLC Conditions for Identification and Content uniformity 
Column: Zorbax SB C18 (150x4.6 )mm   ID, 
5.0µm particle size or equivalent 
(*A column is equivalent if it meets 
the system suitability criteria)                                            
Column Temperature: 40°C± 2.0°C 
Auto-Sampler Temperature: 5°C 
Flow Rate: 1.50 mL/min 
Injection volume: 10 µL 
Detection: UV at 250 nm 
Run time: 35 min 
Elution mode: Gradient elution  
A linear gradient is programmed as described in the following Table 4. 
Table 4: Linear gradient is programme 
Time(min.) 0 20 29 30 35 
% A 90 70 30 90 90 
% B 10 30 70 10 10 
 
Equilibrate HPLC and condition the column with the mobile phase gradient until a 
stable gradient profile is obtained. The system suitability solutions, blank, 
reference solutions and samples are injected according to the current active 
procedure of the executing lab. 
Remarksi 
Use needle wash solvent to avoid carryover 
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Needle Wash: Mixture of Methanol and Formic acid in the ratio 70:30 
v/v. 
Waters HPLC: Extended needle wash mode 
Agilent HPLC: Wash vial filled with needle wash solvent  
Sequence 
It is recommended to purge the injector by injecting at least 6 times 100 µL 
Dilution Solvent. 
The following injections, at a minimum, should be run: 
      Blank injection: inject blank (additional Blanks may be run until an acceptable 
baseline is obtained). 
A. Single injection of Reference Solution 2. 
B. Five successive injections of Reference Solution 1. 
C. Injection(s) of Sample Solution(s) (1 injection per Sample preparation). 
D. Single injection of Reference Solution 1 after 12 or less Sample Solution 
injections and after the last Sample Solution injection (= Control Reference). 
System Suitability 
A. The percent relative standard deviation (% RSD) for the area for Mebendazole of 
five replicate injections of the Reference Solution 1 should be less than or equal to 
2.0 %. 
B. The percentage recovery of Mebendazole in Reference Solution 2 is 98.0% ≤ 
% Recovery ≤ 102.0%.  
C. The percentage recovery of Mebendazole in Reference Solution 3 at the reporting 
threshold value is 70.0% ≤ % Recovery ≤ 130.0%.  
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D. The tailing factor (T) for the Mebendazole peak from first replicate of reference 
solution must be less than 2.0, as calculated by the current USP method 
E. The Resolution factor (R) between (R019020 and R017635) in the selectivity 
solution must be greater than 2.5 as calculated by current USP method. 
F. The reference solution must be injected as a calibration check after each series of 
maximum 12 sample injections and after the last sample injection. The percentage 
Recovery of Mebendazole is 98.0% ≤ % Recovery ≤ 102.0%. 
CHROMATOGRAPHIC CHARACTERISTICS 
The identity of the degradation products are assigned based on a comparision of 
relative retention times (RRT) with the experimentally determined retention times 
listed in the table below. Degradation products are qualified based on the Relative 
Response Factor (RRF). For unspecified and unidentified impurities, not listed in 
the table, the RRF is assumed to be 1.00. 
Model Compounds RRT RT RRF LOD LOQ 
R018986 (*) 0.70 0.10% TBD TBD TBD 
R019020 (**) 0.90 NA NA NA NA 
R017635 (Active) 1.00 0.10% TBD TBD TBD 
(*) degradation product 
(**) system suitability compound or (**) for system suitability only 
TBD: to be determined 
RT: reporting threshold 
LOD: limit of detection 
LOD: limit of Quantitation 
NA: Not applicable 
Guide retention time of mebendazole: Approx. 17.0 minutes 
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List of detectable unspecified products 
Model Compounds RRT 
R039801 (***) 0.76 
R030226 (***) 0.94 
R039553 (***) 1.10 
R018194 (***) 1.19 
R017857 (***) 1.23 
R037725 (***) 1.47 
(***) synthesis impurities 
RT/IT/QT according to ICH 
 Percentage 
RT (=Reporting threshold) 0.10% 
IT (=Identification threshold) 0.20% 
QT (=Qualification threshold) 0.20% 
Chemical Names of impurities and Active 
R018986 (2-amino-1H-benzimidazol-5-yl)phenylmethanone 
R039801 (2-amino-1-methyl-1H-benzimidazol-5-yl)phenylmethanone 
R019020 (2-hydroxy-1H-benzimidazol-5-yl)phenylmethanone 
R017635 Methyl(5-benzoyl-1H-benzimidazol-2-yl)cabamate 
R039553 Methyl(5-benzoyl-1-methyl-1H-benzimidazol-2-yl)cabamate 
R018194 Ethyl(5- benzoyl-1H- benzimidazol-2-yl)cabamate 
R017857 Methyl[5-(4-methylbenzoyl)-1H-benzimidazol-2-yl)cabamate 
R037725 N,N-bis(5-benzoyl-1H- benzimidazol-2-yl)urea 
R030226 N (5-benzoyl-1H- benzimidazol-2-yl) acetamide 
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CALCULATION 
The described formulas are used for manual calculation of the results.  A validated 
chromatographic data system can also be applied. 
For multiple injections the mean of all individual results must be calculated. 
Identification of Mebendazole 
The retention time of Mebendazole in the sample solution is similar to the 
retention time of Mebendazole in the reference solution. 
Second Identification of Mebendazole 
The comparision of the maximum wavelength of the Mebendazole from  
the reference solution and the sample solution must be between ± 2nm. 
Guide wavelength of the Mebendazole: 235nm 
Recovery of Mebendazole 
Calculate the percentage recovery of Mebendazole in the reference solutions 
(control reference solutions and second reference solution), by the formula: 
100% ×××=
rx
x
r
rx
r q
q
r
rD
 
Where, 
Dr Dilution factor = 1 for calculation of Mebendazole in the 
‘second reference solution’ and the ‘control reference 
solution ‘ 
             Dilution factor = 1000 for calculation of Mebendazole in 
the reporting threshold solution’ 
 
qr weight (in mg) of the  Mebendazole reference material in 
the  ‘reference solution’ 
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qrx weight (in mg) of Mebendazole in the ‘second reference 
solution’ or ‘reference solution’ for calculation of control 
references and reporting threshold level  
rrx peak area of Mebendazole in the ‘second reference 
solution’ or ‘control reference solution’  
rr mean peak area of Mebendazole in the ‘reference 
solution’ 
Assay of Mebendazole 
Measure the peak area of Mebendazole in each chromatogram. 
Calculate the quantity (Q in mg) of Mebendazole in the portion of Mebendazole 
chewable tablets 500mg against the stated amount, by the formula: 
rr
m
Fr
r
qrSrQ
'
Pr
×××=
 
Where, 
Sr 2.0 = scaling factor = ratio of volume of sample solution 
to the volume of reference solution (Mebendazole) taking 
into account the dilution. 
qr weight (in mg) of the Mebendazole reference material in 
the  ‘reference solution’ 
rm Peak area of Mebendazole in sample solutions  
rr Mean peak area of Mebendazole in the ‘reference 
solution’ 
Pr              Purity factor of Mebendazole 
F’r            1 = salt/base factor of Mebendazole 
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Calculate the percentage of Mebendazole in the Mebendazole 500mg chewable 
tablets by the formula: 
100% ××=
qs
G
Qth
Q
 
Where, 
G
 
Mean weight (in mg) of one Mebendazole 500mg 
chewable tablets. 
Qth 500 = Theretical conc. of R017635 (in mg/tablet) in 
Mebendazole 500mg chewable tablets. 
qs Weight (in mg) of Mebendazole 500mg chewable tablet 
             Powder in sample solution.   
Assay of Degradation Products 
Calculate the quantity (Qi in mg) of the degradation products and unidentified 
peaks expressed as Mebendazole in the portion of Mebendazole chewable tablets 
500mg taken, by the formula: 
rr
im
Fr
r
qrSiQi
'
Pr
×××=
 
Where, 
Si 2.0 = scaling factor = ratio of volume of sample to the 
volume of reference solution (Mebendazole) taking into 
account the dilution. 
qr weight (in mg) of the  Mebendazole reference material in 
the  ‘reference solution’ 
ri,m Peak area of impurity in sample solutions  
rr Mean peak area of Mebendazole in the ‘reference 
solution’ 
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Pr              Purity factor of Mebendazole 
F’r            1 = salt/base factor of Mebendazole 
 
Calculate the percentage of the impurity in the Mebendazole 500mg chewable 
tablets by the formula: 
1001% ×××=
RRFiqs
G
Qth
Qiimpurity
 
Where, 
G
 
Mean weight (in mg) of one Mebendazole 500mg 
chewable tablets. 
Qth 500 = Theretical conc. of R017635 (in mg/tablet) in 
Mebendazole 500mg chewable tablets. 
qs Weight (in mg) of Mebendazole 500mg chewable tablet 
             Powder in sample solution.   
RRFi Relative response factor of the impurity (expressed as the 
anhydrous parent compound) with regard to mebendazole, 
for unspecified and or unidentified impurities RRFi = 1 
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VALIDATION OF ANALYTICAL METHOD 
 
This validation report summarizes the results of the method validation and 
demonstrates that the test method is suitable for identification and assay of 
R017635 and determination of its impurities in: 
             R017635 G002, Mebendazole Chewable 500mg Tablets. 
The validation characteristics are tested in accordance to the method validation 
protocol DS-VAL-66196, Version: 2.0 
Some numbers are reported with less decimals than those used for the calculations. 
Therefore small differences are possible when results are calculated with the 
numbers as mentioned in this report. 
The compounds that are evaluated during this validation are listed in Table 5. 
Table 5: Table of Compounds 
Compound Batch P F’ Description 
R017635 ZR017635PUA721 0.997 1.000 Reference material 
R018986 FBEN0057_085_3 0.999 1.000 Validated compound  
R019020 COCS_0074_052_1 0.990 1.000 Selected compound 
R030226 COCS0111_087_1 0.996 1.000 Synthesis impurity 
R039553 PROF0001_052_1 0.961 1.000 Synthesis impurity 
R017857 FBEN0056_049_2 0.990 1.000 Synthesis impurity 
R018194 MBER_0005_068_4 0.957 1.000 Synthesis impurity 
R037725 FBEN0056_079_4 0.984 1.000 Synthesis impurity 
R039801 WVLA_0042_099_2 0.994 1.000 Synthesis impurity 
R017635 G002 Smarathe-02-027 NA NA Sample 
R017635 G002 Smarathe-02-025/03 NA NA Sample 
Placebo Smarathe-02-036 NA NA Placebo without Active 
P: purity factor  
F’: salt factor 
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Specificity and Identification 
 
Specificity: Test Results and Acceptance Criteria: 
Specificity is shown by analyzing the following solutions: blank solution, placebo, 
stressed placebo: Batch Smarathe-02-036 stored at 70°C for 5days, stressed 
placebo spiked with 0.50%, w/w all revelant impurities, selectivity solution/SST2, 
reference solution, 0.50%, w/w of each impurity, mixture of each compound in a 
concentration level of 0.50%, w/w next to 100%, w/w of Mebendazole and 
placebo at nominal concentration, sample solution (R017635 G002): batch 
Smarathe-02-027 and stressed samples (R017635 G002): batch Smarathe-02-027 
stored at 70°C for 5 days. 
Peak purity of the Mebendazole is checked by HPLC-PDA. The reference 
solution, the sample solution and the stressed sample solutions must be examined. 
Identification of the Mebendazole is based on retention time will be evaluated over 
the entire method validation. 
Second identification of the Mebendazole with HPLC-PDA will also be 
demonstrated. A reference solution, a sample solution will be analysed.  
Acceptance Criteria: 
To be reported: 
The relative retention time (RRT) of each compound is reported and specificity is 
shown by means of an overlay of the chromatograms. 
Criteria: 
Table 6: Specificity: Acceptance criteria 
Parameter Criteria 
Blank peaks Preferably absent  
Placebo peaks 
 
Should be separated from 
Mebendazole and from the 
specified/validated impurities 
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Validated impurities Should be separated from 
Mebendazole and from each other 
Selected impurities Should be separated from 
Mebendazole and from the validated 
impurities. 
 
 
Parameter Criteria 
Peak purity of API using PDA The UV spectra of Mebendazole at 
front, middle and tail are comparable 
or peak purity is calculated with 
software (Empower) and should 
confirm that the peak of the 
Mebendazole is pure. The Purity 
Angle (PA) must be smaller than the 
Purity Threshold (PT) 
  
 
Table 7: Identification: Acceptance criteria 
Parameter Criteria 
Identification of the Mebendazole  based 
on retention time 
Matching retention time windows 
(±5% of retention time of  reference) 
Identification of the Mebendazole  with 
HPLC-PDA 
The maximum of the spectrum of the 
Mebendazole in the sample may not 
differ more than 2 nm from the 
maximum of the spectrum of the 
Mebendazole in the reference. The 
profiles of the spectra of sample and 
reference must correspond. No 
interference of placebo. 
 
Test Results for specificity: 
Elution order has been determined for the impurities 
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Table 8: Relative Retention Times  
Compound Relative Retention Time 
R018986: Validated compound 0.70 
R019020: Selected compound 0.92 
R039801: Synthesis impurity 0.76 
R030226: Synthesis impurity 0.94 
R039553: Synthesis impurity 1.09 
R018194: Synthesis impurity 1.19 
R017857: Synthesis impurity 1.23 
R037725: Synthesis impurity 1.46 
R017635: Mebendazole (API) 1.00 
 
 No blank peak interferes with peaks of interest. 
 All placebo peaks are separated from Mebendazole and from the 
specified/validated impurity. 
 All validated impurity are separated from Mebendazole and from each other. 
 The selected impurities are separated from Mebendazole and from the 
validated impurity. 
The peak purity confirms (result from Empower software) that the peak of the 
Mebendazole is pure because the purity angle (PA) is smaller than the 
purity threshold (PT).  
Table 9: Specificity: Peak Purity of Mebendazole by PDA 
Sample Peak Purity 
Reference solution Pass 
Sample solution (R017635 G002): batch Smarathe-02-027 Pass 
Stressed sample (R017635 G002): batch Smarathe-02-027, 
stored at 70°C for 5 days. 
Pass 
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Fig 8: Specificity: Overlay Chromatograms of the mixture, the selectivity solution and the 
separately injected impurities.  
 
 
 
Fig 9:   Specificity: Overlay Chromatograms of blank, placebo, reference solution at reporting 
threshold, reference solution at 100% and Mixture of each compound in a 
concentration level of 0.50 %, w/w next to 100.0 %, w/w of Mebendazole and placebo 
at nominal concentration.    
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Fig 10: Specificity: Overlay Chromatograms of placebo, stressed placebo (batch Smarathe-02-
036 stored at 70 °C for 5 days), stressed placebo spiked with 0.5%w/w all relevant 
impurities, sample solution (R017635 G002): batch Smarathe-02-027, stressed sample 
(R017635 G002): batch Smarathe-02-027 stored at 70°C for 5 days. 
                           
 
 
 
 
Test results for Identification of the Mebendazole based on retention time: 
The retention time windows were evaluated over the entire method validation. The 
retention time range of the Mebendazole in the sample solution is ± 5% of the 
retention time of the Mebendazole in the first injection of the reference solution. 
Test results for Identification of the Mebendazole with HPLC-PDA: 
 
Table 10: Identification of Mebendazole with HPLC-PDA 
Solution Maximum Criteria 
Placebo -  
Reference solution  235.3 nm  
Sample (R017635 G002) batch smarathe-02-027 235.3 nm  
Difference between the maximum wavelength of the 
spectrum of the Mebendazole in the sample solution 
and the maximum wavelength of the spectrum of the 
Mebendazole in the reference solution 
0 nm  ≤ 2nm 
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 The profile of the spectra of spiked placebo/sample and reference 
corresponds. 
 No interference of placebo. 
Conclusion: 
The results prove that the method is specific and can be used for identification of 
the Mebendazole.  
 
 
 
 
 
 
 
 
System Repeatability (Precision):  Mebendazole 
System Repeatability: Test Results and Acceptance Criteria: 
The system repeatability is calculated as % RSD of 5 injections of the same reference solution. 
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Table 11: System Repeatability 
Determination 
Area Counts 
µV.sec 
1 2911272 
2 2937799 
3 2921722 
4 2895892 
5 2898414 
Mean: 2913020 
  
 RSD (%) Criterion (%) 
 0.6 ≤ 1.0 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS                                                                                  BY RP - HPLC 
 
Dept. of Pharmaceutical Analysis, EGSPCP                                                                                        Page | 76 
 
Accuracy and Analysis Repeatability (Precision):  Mebendazole 
 
Accuracy and Precision: Active (Mebendazole) 
Accuracy at high concentration levels: Test Results and Acceptance 
Criteria: 
The accuracy is assessed using 9 determinations covering the specified range at 
3 concentration levels: 80.0, 100.0 and 120.0%, w/w. Each concentration is 
prepared 3 times by separate weighing and contains placebo at 100% level. The 
accuracy is calculated as the % recovery and the mean recovery is calculated at 
each concentration level. 
Table 12: Accuracy: At high Concentration Levels 
Concentration 
Theoretical (%) 
Concentrati
on Practical 
(mg/mL) 
Area 
Counts 
µV.sec 
Recover
y 
(%) 
Criteria 
 (%) 
80.0 %  (1) 0.08031 2347049 100.2  97.0-103.0 
80.0 %  (2) 0.08095 2365725 101.0 97.0-103.0 
80.0 %  (3) 0.08140 2379077 101.7 97.0-103.0 
Mean recovery:   101.0  98.0-102.0 
     
100.0 %  (1)  0.1017 2972730 101.6 97.0-103.0 
100.0 %  (2) 0.1014 2963285 101.3 97.0-103.0 
100.0 %  (3) 0.1014 2963687 101.4 97.0-103.0 
Mean recovery:   101.4 98.0-102.0 
     
120.0 %  (1)  0.1196 3497668 99.6 97.0-103.0 
120.0 %  (2) 0.1215 3551706 101.2 97.0-103.0 
120.0 %  (3) 0.1213 3545434 101.0 97.0-103.0 
Mean recovery:   100.6 98.0-102.0 
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Analysis Repeatability at high concentration levels: Test Results and 
Acceptance Criteria: 
The Mebendazole at high concentration level analysis repeatability is assessed 
using 9 determinations covering the specified range at 3 concentration levels 
(80.0-120.0%). The analysis repeatability is calculated as % RSD at individual 
concentration level. 
Table 13: Analysis Repeatability: Mebendazole: batch ZR017635PUA721 
Concentration        
Theoretical (%) 
qs 
(mg) 
Area 
Counts 
µV.sec 
Recovery  
(%) 
80.0 %  (1) 80.39 2347049 100.2051 
80.0 %  (2) 80.37 2365725 101.0276 
80.0 %  (3) 80.29 2379077 101.6690 
    
Mean:               101.0 
    
   RSD (%) Criterion (%) 
   0.7 ≤ 2.0  
 
 
Table 14: Analysis Repeatability: Mebendazole: batch ZR017635PUA721 
Concentration        
Theoretical (%) 
qs 
(mg) 
Area 
Counts 
µV.sec 
Recovery  
(%) 
100.0 %  (1)  100.40 2972730 101.6228 
100.0 %  (2) 100.43 2963285 101.2697 
100.0 %  (3) 100.30 2963687 101.4147 
    
Mean:   101.4 
    
   RSD (%) Criterion (%) 
   0.2 ≤ 2.0  
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Table 15: Analysis Repeatability: Mebendazole: batch ZR017635PUA721 
Concentration        
Theoretical (%) 
qs 
(mg) 
Area 
Counts 
µV.sec 
Recovery 
(%) 
120.0 %  (1)  120.54 3497668 99.5904 
120.0 %  (2) 120.50 3551706 101.1625 
120.0 %  (3) 120.43 3545434 101.0426 
    
Mean:   100.6 
    
   RSD (%) Criterion (%) 
   0.9 ≤ 2.0 % 
 
 
Accuracy and Analysis Repeatability at low concentration levels: Test Results 
and Acceptance Criteria: 
The Mebendazole at low concentration levels and the validated impurities analysis 
repeatability is assessed using 9 determinations covering the specified range at 
3 concentration levels: 0.10%, 0.50% and 1.0% %, w/w. Each concentration is 
prepared 3 times by serial dilutions of 3 separately prepared stock solutions and 
contains placebo at 100% level. The accuracy is calculated as the % recovery. The 
analysis repeatability is calculated as % RSD. 
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Table 16: Accuracy and Analysis Repeatability: At Low Concentration Levels 
Concentration 
Theoretical (%) 
Concentrati
on Practical 
(mg/mL) 
Area 
Counts 
µV.sec 
Recover
y  
(%) 
Criteria 
 (%) 
0.10 %  (1) 0.0001097 3179 109.8098 NA 
0.10 %  (2) 0.0001077 3123 107.2709 NA 
0.10 %  (3) 0.0001149 3329 114.4422 NA 
Mean recovery:   110.5 80.0-120.0 
RSD (%):         3.3 ≤ 10.0 
     
0.50 %  (1) 0.0005199 15064 104.0840 NA 
0.50 %  (2) 0.0005185 15023 103.2251 NA 
0.50 %  (3) 0.0005206 15085 103.6845 NA 
Mean recovery:   103.7 90.0-110.0 
RSD (%):   0.4 ≤ 5.0 
     
1.0 %  (1) 0.001024 29672 102.5127 NA 
1.0 %  (2) 0.001038 30090 103.3641 NA 
1.0 %  (3) 0.001016 29459 101.2346 NA 
Mean recovery:   102.4 90.0-110.0 
RSD (%):   1.0 ≤ 5.0 
NA = Not applicable 
 
 
Accuracy and Analysis Repeatability (Precision):  Impurity(R018986) 
 
Accuracy and Precision: Validated Impurity 
Accuracy and Analysis Repeatability: Test Results and Acceptance 
Criteria 
The accuracy and analysis repeatability are assessed using 9 determinations 
covering the specified range at 3 concentration levels: 0.10, 0.50 and 1.0%, w/w. 
Each concentration is prepared 3 times by serial dilutions of 3 separately prepared 
stock solutions and contains placebo and Mebendazole at 100% level. 
The impurities present in an un-spiked Mebendazole solution at 100.0% level are 
taken into account.  
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The accuracy is calculated as the mean recovery at each concentration level 
(relative response factor is taken into account). The analysis repeatability is 
calculated as % RSD. 
Table 17: Accuracy and Analysis Repeatability – R018986 
Concentration  
Theoretical (%) 
Concentrati
on Practical 
(mg/mL) 
Actual 
Area 
Counts 
µV.sec 
Recover
y  
(%) 
Criteria (%) 
0.10 % (1) 0.0001037 2697 102.2682 NA 
0.10 % (2) 0.0001016 2642 100.9940 NA 
0.10 % (3) 0.0001030 2679 102.3856 NA 
Mean recovery:   101.9 80.0-120.0 
RSD (%):   0.8 ≤ 10.0 
     
0.50 % (1) 0.0005020 13049 98.9552 NA 
0.50 % (2) 0.0004970 12919 98.8071 NA 
0.50 % (3) 0.0004960 12892 98.5887 NA 
Mean recovery:   98.8 90.0-110.0 
RSD (%):   0.2 ≤ 5.0 
     
1.0 % (1) 0.001006 26155 99.1721 NA 
1.0 % (2) 0.0009796 25460 97.3757 NA 
1.0 % (3) 0.0009894 25715 98.3303 NA 
Mean recovery:   98.3 90.0-110.0 
RSD (%):   0.9 ≤ 5.0 
NA = Not applicable 
 
Conclusion: 
All the results are within acceptance criteria and prove the suitability of the 
method for an accurate and precise determination of the impurities. 
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Reproducibility 
 
Reproducibility: Test Results and Acceptance Criteria for Assay 
Two analysts (Analyst-1 from Kemwell Lab, India and Analyst-2 from QC- Lab, 
Lusomedicamenta) analyzed the same 2 representative sample batches 6 times: 
batch Smarathe-02-027 and batch Smarathe-02-025/03 both spiked with 
approximately 0.50% of the validated impurity R018986. One un-spiked sample 
preparation is analysed by each analyst. The analysts used different instruments, 
different batches of columns and performed the analysis on different days. The 
reproducibilty is calculated as % RSD of each analyst, the % pooled RSD and % 
absolute difference between the 2 determinations. 
Table 18:  Reproducibility: Mebendazole  in batch  Smarathe-02-027  
Date: 
HPLC: 
Column Batch: 
Analyst  
19/10/2013 
ADII/HPLC/04 
B12020 (AD/LC/0433) 
M. Sankar (Analyst-1) 
03/11/2013 
QC412A 
B11055 (LC870) 
Guinesh Natvarlal  (Analyst-2) 
Determination qs 
(mg) 
Area 
Counts 
µV.sec 
Assay (%) qs (mg) 
Area 
Counts 
µV.sec 
Assay (%) 
Unspiked 200.18 2797977 97.1 202.71 2804444 96.7 
1 200.20 2793893 96.9 195.77 2675497 95.5 
2 200.42 2804956 97.2 200.62 2792630 97.3 
3 200.60 2812518 97.4 200.78 2777521 96.7 
4 200.52 2791884 96.7 200.72 2803522 97.6 
5 200.26 2799864 97.1 200.20 2774109 96.9 
6 200.69 2798108 96.8 201.43 2785450 96.7 
       
Mean:   97.0   96.8 
       
    Result (%) Criterion (%) 
   
% absolute 
difference  0.2 ≤ 3.0 
   
RSD of 
analysts  0.3 ≤ 2.0 
   
Pooled 
RSD 0.6 ≤ 3.0 
G (average weight of the 10 tablets) – Analyst 1: 1000.39mg 
G (average weight of the 10 tablets) – Analyst 2: 999.668mg 
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Table 19:  Reproducibility: Mebendazole  in batch  Smarathe-02-025/03 
Date: 
HPLC: 
Column Batch: 
Analyst 
20/10/2013 
ADII/HPLC/04 
B12020 (AD/LC/0433) 
M. Sankar (Analyst-1) 
03/11/2013 
QC412A 
B11055 (LC870) 
Guinesh Natvarlal  (Analyst-2) 
Determination qs 
(mg) 
Area 
Counts 
µV.sec 
Assay (%) qs (mg) 
Area 
Counts 
µV.sec 
Assay (%) 
Unspiked 199.89 2808481 97.9 200.56 2766438 97.0 
1 200.48 2830843 98.4 202.20 2813324 97.9 
2 200.41 2833195 98.5 200.85 2789148 97.7 
3 200.50 2850919 99.1 200.59 2806909 98.4 
4 200.67 2853743 99.1 200.76 2808923 98.4 
5 200.46 2836191 98.6 200.43 2799253 98.3 
6 200.18 2834703 98.7 200.81 2785401 97.6 
       
Mean:   98.7   98.1 
       
    Result (%) Criterion (%) 
   
% absolute 
difference  0.6 ≤ 3.0 
   
RSD of 
analysts  0.3 ≤ 2.0 
   
Pooled 
RSD 0.3 ≤ 3.0 
G (average weight of the 10 tablets) – Analyst1: 1008.12mg 
G (average weight of the 10 tablets) – Analyst2: 1006.102mg 
 
As the reproducibility is incorporated in the method validation the identification of 
the Mebendazole by HPLC (based on retention times) and the second 
identification of the Mebendazole by HPLC-PDA are verified by the receiving 
laboratory (QC Lab, Lusomedicamenta). The retention time windows were 
evaluated for both batches. The retention time range of the Mebendazole in the 
sample solution is ±5% of the retention time of the Mebendazole in the first 
injection of the reference solution. The second identification test is performed on 
one sample of batch Smarathe-02-07 according to the test method. 
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Table 20: Identification of Mebendazole with HPLC-PDA 
Solution Maximum Criteria 
Reference solution 234.9 nm  
Sample (batch Smarathe-02-027) 234.9 nm  
Difference between the maximum wavelength of the spectrum of 
the Mebendazole in the sample solution and the maximum 
wavelength of the spectrum of the Mebendazole in the reference 
solution. 
0 nm ≤ 2nm 
 
During reproducibility a different terminology was not used for the formulas 
mentioned in the test method. So Equivalency was not demonstrated and not 
documented in the lab notebook. 
Conclusion: 
All the results are within acceptance criteria and prove the suitability of the 
method for an accurate and precise determination of the API. 
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Reproducibility: Test Results and Acceptance Criteria for Chromatographic purity 
Two analysts (Analyst-1 from Kemwell Lab, India and Analyst-2 from QC- Lab, 
Lusomedicamenta) analyzed the same 2 representative sample batches 6 times: batch Smarathe-
02-027 and batch Smarathe-02-025/03 both spiked with approximately 0.50% of the validated 
impurity R018986. One un-spiked sample preparation is analysed by each analyst. The analysts 
used different instruments, different batches of columns and performed the analysis on different 
days. The reproducibilty is calculated as % RSD of each analyst, % Relative difference and  % 
pooled RSD between the 2 determinations. 
For impurities that are spiked to the samples, use the second table. 
Table 21: Reproducibility: R018986 in Batch Smarathe-02-027 
Date: 
HPLC: 
Column Batch: 
Analyst  
19/10/2013 
ADII/HPLC/04 
B12020 (AD/LC/0433) 
M. Sankar  (Analyst-1) 
03/11/2013 
QC412A 
B11055 (LC870) 
Guinesh Natvarlal  (Analyst-2) 
Determination qs (mg) 
Area 
Counts 
µV.sec 
% 
Impurity 
qs 
(mg) 
Area 
Counts 
µV.sec 
% Impurity 
1 200.20 13029 0.4986 195.77 13133 0.4722 
2 200.42 13017 0.4982 200.62 13567 0.4889 
3 200.60 13003    0.4977 200.78 13706         0.4941 
4 200.52 13017 0.4982 200.72 13829 0.4988 
5 200.26 13096 0.5012 200.20 13831 0.4989 
6 200.69 12981 0.4968 201.43 13720 0.4946 
     
Mean:  0.4985  0.4912 
Un-spiked 200.18 653 0.02499 202.71  0.0290 
     
   Result (%) Criterion (%) 
  % relative 
difference 1.5 ≤ 20.0 
  % absolute 
difference    NA NA 
  RSD of 
analysts 0.3 ≤ 5.0 
  Pooled 
RSD 1.4 ≤ 10.0 
qi (weight impurity in stock solution) – Analyst 1/Analyst 2: 5.063 mg/5.115 mg 
Volume impurity stock solution: 200 mL 
Dilution factor impurity stock solution: 10000 
Volume reference solution: 50 mL 
Dilution factor reference solution: 500 
%Spiking level: 0.50 
NA = Not applicable 
 
MATERIALS AND METHODS                                                                                  BY RP - HPLC 
 
Dept. of Pharmaceutical Analysis, EGSPCP                                                                                        Page | 85 
 
 
 
Table 22: Reproducibility: R018986 in Batch Smarathe-02-025/03 
Date: 
HPLC: 
Column Batch: 
Analyst  
20/10/2013 
ADII/HPLC/04 
B12020 (AD/LC/0433) 
M. Sankar  (Analyst-1) 
03/11/2013 
QC412A 
B11055 (LC870) 
Guinesh Natvarlal  (Analyst-2) 
Determination qs (mg) 
Area 
Counts 
µV.sec 
% 
Impurity 
qs 
(mg) 
Area 
Counts 
µV.sec 
% Impurity 
1 200.48 13066 0.4954 202.20 13948 0.5032 
2 200.41 12978 0.4921 200.85 13894 0.5011 
3 200.50 13071    0.4956 200.59 13720 0.4945 
4 200.67 13082 0.4960 200.76 13718 0.4944 
5 200.46 12964 0.4915 200.43 13495 0.4860 
6 200.18 13044 0.4946 200.81 13642 0.4915 
     
Mean:  0.4942  0.4951 
Un-spiked 199.89 708 0.0268 200.56 753 0.0290 
     
   Result (%) Criterion (%) 
  % relative 
difference 0.2 ≤ 20.0 
  % absolute 
difference NA NA 
  RSD of 
analysts 0.4 ≤ 5.0 
  Pooled 
RSD 0.9 ≤ 10.0 
qi (weight impurity in stock solution) – Analyst 1/Analyst 2: 5.089 mg/5.115 mg 
Volume impurity stock solution: 200 mL 
Dilution factor impurity stock solution: 1000 
Volume reference solution: 50 mL 
Dilution factor reference solution: 500 
%Spiking level: 0.50 
NA = Not applicable 
 
No unspecified impurities are detected equal to or greater than the reporting threshold of the 
method (= 0.10 %, w/w). 
During reproducibility a different terminology was not used for the formulas mentioned in the test 
method. Equivalency was not demonstrated and not documented in the lab notebook. 
Conclusion: 
All the results are within acceptance criteria and prove the suitability of the method for an 
accurate and precise determination of the impurities. 
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Detection Limit (DL) and Quantitation Limit (QL) 
 
Detection Limit: 
The DL is demonstrated on a solution containing both API and the validated 
impurities at DL level. 
Test results - DL 
Table 23: DL values 
Compounds DL value (%) 
Mebendazole – R017635 0.01 
R018986 0.003 
 
Quantitation Limit: 
Test Results and Acceptance Criteria 
The QL value is set equal to the reporting threshold value and is supported by the 
accuracy and analysis repeatability at RT level.  
Table 24:  QL values 
Compounds Criteria QL value (%) 
Mebendazole – R017635 See 0 0.02 
R018986 See 0 0.01 
Conclusion: 
The quantitation limits are reported. The accuracy and analysis repeatability at the 
RT level proves an accurate and precise determination of impurities at the lower 
concentration level. 
 
Reporting Threshold 
 
Reporting Threshold: 
The reporting threshold is 0.10%, w/w. Accuracy and analysis repeatability are 
demonstrated at this level. 
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Linearity 
Linearity: Test Results and Acceptance Criteria 
For the Mebendazole the linearity is demonstrated on the following 
concentrations:  
0.10 – 0.50 – 1.0 – 5.0 – 25.0 – 80.0 – 90.0 – 100.0 – 110.0 – 120.0%, w/w. 
For the validated impurity the linearity is demonstrated on the following 
concentrations: 0.10 – 0.20 – 0.50 – 0.80 – 1.0%, w/w. 
Linearity is evaluated by visual inspection of a plot and mathematical estimates of 
the degree of linearity. 
Table 25: Linearity 
Reference r Criteria % 
RSD* 
Criteria 
(%) 
Visual 
R018986: 0.10% - 1.0% 0.999 ≥ 0.99 2.3 ≤ 15.0 Linear 
Mebendazole: 80.0% - 
120.0% 0.999 ≥ 0.999 0.4 ≤ 3.0 Linear 
Mebendazole: 0.10% - 
120.0% 0.999 ≥ 0.99 5.6 ≤ 10.0 Linear 
*: RSD on response factors 
 
 
Table 26: Linearity Mebendazole (0.10 % - 120.0 %) 
Concentration API 
Theoretical (%) 
Concentration 
API  
Practical  
(mg/mL) 
Actual 
Area 
Counts 
µV.sec 
Response Factor 
(Area Counts / 
Concentration  
mg/mL) 
0.10 0.0001000 3290 32900000.0000 
0.50 0.0004999 13987 27979595.9191 
1.0 0.0009998 27905 27910582.1164 
5.0 0.0049990 140344 28074414.8829 
25.0 0.0249948 708526 28346936.1627 
80.0 0.0799833 2233098 27919553.2067 
90.0 0.0899812 2489529 27667212.7066 
100.0 0.0999792 2784319 27848982.5883 
110.0 0.1099771 3051219 27744130.3689 
120.0 0.1199750 3349328 27916882.6838 
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Fig 11: Linearity Mebendazole (0.10% - 120.0%) 
 
 
Y-axis : Area counts in µV.sec 
X-axis : Concentration in mg/ml 
Slope : 27806214.1462 
Intercept : 2283.9708 
Residual Sum of Squares : 612381728.8841 
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Fig 12: Linearity Mebendazole (80.0% - 120.0%) 
 
 
 
  
Y-axis : Area counts in µV.sec 
X-axis : Concentration in mg/ml 
Slope : 27947285.3005  
Intercept : -12647.5086 
Residual Sum of Squares : 449307614.8291 
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Table 27:  Linearity validated impurity R018986 (0.10% - 1.0%) 
Concentration 
Theoretical (%) 
Concentration 
Practical  
(mg/mL) 
Area 
Counts 
µV.sec 
Response Factor  
(Area Counts /  
Concentration mg/mL) 
0.10 0.0001029 2648 25733722.0602 
0.20 0.0002057 5236 25454545.4545 
0.50 0.0005143 13230 25724285.4365 
0.80 0.0008229 20032 24343176.5706 
1.0 0.0010286 26269 25538596.1501 
 
Fig 13:   Linear graph R018986 (0.10% - 1.0%) 
 
Y-axis : Area counts in µV.sec 
X-axis : Concentration in mg/ml 
Slope : 25075207.9206 
Intercept : 70.7728 
Residual Sum of Squares : 687131.2320 
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Conclusion: 
All acceptance criteria are met demonstrating the linearity of the method. 
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Range 
Range: Test Results and Acceptance Criteria 
The range of the test method describes the interval between the upper and lower 
concentration for which it has been demonstrated that the test method has a 
suitable level of accuracy, precision and linearity. 
Test Results and Acceptance Criteria:  Range 
Table 28: Range 
Compounds Target Range 
Mebendazole 0.10 % - 120.0% 
R018986 0.10 % - 1.0 % 
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Robustness 
Robustness: Test Results and Acceptance Criteria 
The robustness of the chromatographic conditions is tested by varying the 
following parameters: column temperature (± 5°C), flow (± 0.20 ml/min), start of 
gradient (± 1 unit), concentration of mobile phase A (± 0.0025% TFA), based on 
the development data Experiment -11, 12, 13 and 14 are worst case experiments 
percentage organic modifier in the mobile phase at the start of the gradient. 
Table 29: Robustness  
Parameter Resolution (Rs)  
R019020-R017635 
Tailing Factor (T)  
Mebendazole 
Nominal 6.4 1.0 
Flow rate 1.3mL/min 6.6 1.0 
Flow rate 1.7mL/min 6.4 1.0 
Column Lot: B 6.5 1.0 
Column temperature 35°C 6.2 1.0 
Column temperature 45 °C 7.4 1.0 
Gradient : -1unit 6.7 1.0 
Gradient : +1unit 6.5 1.0 
Mobile phase TFA 0.0225% 7.5 1.0 
Mobile phase TFA 0.0275% 6.9 1.0 
Exp. No: 11 7.4 1.0 
Exp. No: 12 8.2 1.0 
Exp. No: 13 5.9 1.0 
Exp. No: 14 6.7 1.0 
The robustness of the sample preparation is tested by varying the following 
parameters: the way of sonication time variation (± 5 minutes), by addition of 
formic acid volume (±5 mL) of the sample preparation.  
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Table 30: Robustness sample preparation  (Sample: batch Smarathe-02-027) 
Parameter G 
(mg) 
qs 
(mg) 
Area 
Counts 
µV.sec 
Assay 
(%) 
%Absolute 
Difference 
Sample preparation 
technique  (Nominal) 
999.81 200.29 2777034 97.6   NA 
Sonication time: 15minutes 999.81 200.25 2762804 97.1 0.5 
Sonication time: 25minutes 999.81 200.53 2788114 97.9 0.3 
Formic acid: 25mL 999.81 200.42 2766037 97.2 0.4 
Formic acid: 35mL 999.81 200.07 2774776 97.7 0.1 
    
Criterio
n: 
≤ 3.0% 
NA = Not applicable 
G = average weight of the 10 tablets 
 
Conclusion: 
The worst case Resolution of 2.5 is set as minimum system suitability acceptance 
criterion. A worst case experiment (low column temperature in combination with 
low flow and less concentration of TFA) was set up to determine this acceptance 
criterion. 
A Limit of < 2.0 is set as system suitability solution acceptance ctiterion for the 
Tailing factor. 
The Assay values of the different sample preparations are all within 3.0% absolute 
difference compared to the nominal value. 
The robustness of the method is demonstrated by proving the validity of the 
method after small deliberate changes to the method parameters. 
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Stability of Solutions 
Stability of solutions: Test Results and Acceptance Criteria 
The stability of the reference solution, un-spiked sample and spiked sample 
solution (spiked with the validated impurities) is determined during a period of 
7 days. The solutions are stored in amber glassware at ambient conditions on table 
top and at 2-8°C condition. 
Test Results and Acceptance Criteria 
Table 311: Stability of Solutions  
Solution  t = 0 t = 1 day (Table Top) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference  Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 2836245 99.7 0.3 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2786958 97.8 0.3 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 1174 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 13881 0.54 1.9 ≤ 15.0 
No New degradation products at t = 1 days Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
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Table 322: Stability of Solutions (continued) 
Solution  t = 0 t = 1 day (2-8°C) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 2835582 99.7 0.3 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2787588 97.8 0.3 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 769 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 13466 0.53 0.0 ≤ 15.0 
No New degradation products at t = 1 days Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
 
 
Table 333:  Stability of Solutions (continued) 
Solution  t = 0 t = 2 day (Table Top) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 3019272 105.0 5.0 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2808073 97.5 0.6 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 1802 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 14776 0.57 7.5 ≤ 15.0 
No New degradation products at t = 2 days Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
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Table 344: Stability of Solutions (continued) 
Solution  t = 0 t = 2 day (2-8°C) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 2860372 99.5 0.5 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2806316 97.4 0.7 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 921 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 13773 0.53 0.0 ≤ 15.0 
No New degradation products at t = 2 days Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
 
Table 35: Stability of Solutions (continued) 
Solution  t = 0 t = 3 day (Table Top) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 NA NA NA ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2786199 97.3 0.8 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 1784 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 14680 0.57 7.5 ≤ 15.0 
New degradation products at t = 3 days: < RT Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
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Table 36: Stability of Solutions (continued) 
Solution  t = 0 t = 3 day (2-8°C) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 2842335 99.5 0.5 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2783167 97.2 0.9 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 775 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 13654 0.53 0.0 ≤ 15.0 
New degradation products at t = 3 days: < RT Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
 
 
Table 375: Stability of Solutions (continued) 
Solution  t = 0 t = 5 day (Table Top) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 NA NA NA ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2805670 98.5 0.4 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 2334 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 15323 0.60 13.2 ≤ 15.0 
New degradation products at t = 5 days: < RT Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
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Table 386: Stability of Solutions (continued) 
Solution  t = 0 t = 5 day (2-8°C) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 2842827 100.0 0.0 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2778290 97.6 0.5 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 816 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 13503 0.53 0.0 ≤ 15.0 
New degradation products at t = 5 days: < RT Pass 
G (average weight of the 10 tablets for sample solution): 999.81mg 
 
Table 397: Stability of Solutions (continued) 
Solution  t = 0 t = 7 day (Table Top) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 NA NA NA ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2877533 99.9 1.8 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 3643 0.14 > RT ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 16823 0.65 22.6 ≤ 15.0 
New degradation products at t = 7 days: < RT Pass 
G (average weight of the 10 tablets for Sample Solution): 999.81mg 
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Table 40: Stability of Solutions (continued) 
Solution  t = 0 t = 7 day (2-8°C) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Reference Solution Conc. (mg/ml) 
Area 
counts 
µV.sec 
Recovery 
(%) 
Area 
counts 
µV.sec 
Recovery 
(%)   
Reference solution 
100% level 0.10004 2824960 100.0 2874740 100.0 0.0 ≤ 2.0 
Assay - unspiked 
sample solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Assay 
(%) 
Area 
counts 
Assay 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
Mebendazole 200.42 2776662 98.1 2830868 98.3 0.2 ≤ 2.0 
Degradation products 
unspiked sample 
solution (batch 
Smarathe-02-027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.42 747 < RT 1147 < RT NA ≤ 20.0 
Degradation products 
spiked sample solution 
(batch Smarathe-02-
027)   
qs 
(mg) 
Area 
counts 
Impurity 
(%) 
Area 
counts 
Impurity 
(%) 
Rel.  
Diff. (%) 
Criteria 
(%) 
R018986 200.39 13421 0.53 14066 0.54 1.9 ≤ 15.0 
New degradation products at t = 7 days: < RT Pass 
G (average weight of the 10 tablets for Sample Solution): 999.81mg 
Conclusion: 
Acceptance solution stability has been demonstrated for reference solution at 
100% level, sample solution unspiked and sample solution spiked with the 
validated impurity at 0.50% level during a period of 7 days when stored in amber 
glassware at 2-8°C condition 
Solution stability of reference solution at 100% level were not meeting the 
acceptance criteria on table top at 2nd day.Hence the reference solution at 100% 
level is stable for one day.  
Sample solution unspiked and sample solution spiked with the validated impirity 
at 0.50% level at ambient conditions were not meeting the acceptance criteria on 
table top at 7th day. Hence sample solution unspiked and sample solution spiked 
with the validated impirity at 0.50% level is stable upto 5 days. 
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Filtration Study 
Stability of solutions: Test Results and Acceptance Criteria 
Filtrates collected from the sample solution (spiked with approximately 0.50% 
validated impurities) and a blank are analyzed and compared with centrifuged 
(unfiltered) samples of the same solutions. 
Table 41: Filtration study 
Spiked Sample 
Solution (batch 
Smarathe-02-027) 
 
Filtered 
 
Centrifuged 
 
Rel.  
Diff.  
(%) 
Criteria 
(%) 
 qs 
(mg) 
Area 
counts 
µV.sec 
Assay 
(%) 
Area 
counts 
µV.sec 
Assay 
(%) 
  
Mebendazole 200.20 2791483 96.8 2793699 96.9 0.1 ≤ 2.0 
 qs 
(mg) 
Actual 
Area 
counts 
µV.sec 
Impurity 
(%) 
Area 
counts 
µV.sec 
Impurity 
(%) 
  
R018986 5.063 12975 0.4966 13065 0.5000 0.7 ≤ 15.0 
Contaminants must be smaller than 0.10% Pass 
G (average weight of the 10 tablets for Sample Solution): 1000.39mg 
Conclusion: 
The filtration study demonstrates the absence of interfering contaminants extracted 
from the filter and the absence of significant adsorbance to the filter bed. 
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Relative Response Factors 
Stability of solutions: Test Results  
The Relative Response Factors (RRF) are calculated from the slopes of the 
calibration curves of the validated impurities in the specified range and the API in 
the assay range. 
range)(assay  API
range) (specifiedImpurity 
Slope
Slope
RRF =  
 
Table 428: Calculation of RRF values 
Compound Range Slopes RRF 
Mebendazole 80.0 – 120.0% 27947285.3005 - 
R018986 0.10 – 1.0% 25075207.9206 0.897 
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Forced degradation Study 
A forced degradation study was conducted to demonstrate that the method is 
stability indicating. Separate portions of drug product, drug substance and placebo 
were exposed to following stress condition to induce degradation. 
Acid Stress: (For sample) 
1) Samples were stressed with 5mL of 1N HCl at 80°C for 2 hours, 
neutralized with 5ml of 1N NaOH. 
(% degradation was not achieved)  
2) Samples were stressed with 10mL of 1N HCl at 80°C for 3 hours, 
neutralized with 10ml of 1N NaOH. (% degradation was not achieved)  
3) Samples were stressed with 5mL of 5N HCl at 80°C for 2 hours, 
neutralized with 5ml of 5N NaOH.  
(% degradation was achieved)  
Base Stress: (For sample) 
1) Samples were stressed with 2.5mL of  0.5N NaOH at 80°C for 2 hours, 
neutralized with 2.5ml of 0.5N HCl. (% degradation was not achieved) 
2) Samples were stressed with 5mL of 0.5N NaOH at 75°C for 45mins, 
neutralized with 5ml of 0.5N HCl. (% degradation was not achieved)  
Oxidative Stress: (For sample) 
1)  Samples were stressed with 5mL of 1% hydrogen peroxide (H2O2) at 80°C 
for 1 hour. 
      (% degradation was not achieved). 
2) Samples were stressed with 5mL of 3% hydrogen peroxide (H2O2) at 70°C 
for 1 hour. 
       (% degradation was not achieved). 
3) Samples were stressed with 5mL of 3% hydrogen peroxide (H2O2) at 80°C 
for 50mins. 
       (% degradation was not achieved). 
Thermal Stress: (For sample) 
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Samples were exposed to heat at 80°C for about 72hrs. 
Photolytic stress: (For sample) 
Photolytic degradation study was carried out by exposing the samples to light 
providing an overall illumination of not less than 1.2 million lux hours and an 
integrated near ultraviolet energy of not less than 200 watt hours / square meter. 
(Neutronic photo stability chamber - by using light source option 2) 
Stressed samples were injected into the HPLC system with photo diode array 
detector by following methodology section given in the protocol.  
No Interference was observed from diluent and placebo peaks at the retention time 
of Mebendazole peak. 
The chromatograms of the stressed test samples were evaluated for peak purity of 
Mebendazole peak using Waters Empower networking software. For all forced 
degradation test solutions, the purity angle is less than the purity threshold for the 
Mebendazole peak. 
The results obtained are given in Table 5 and Table 6.  
Results obtained from forced degradation studies for sample 500mg strength are 
summarised in Table 43. 
Table 43:    
Mode of 
degradation 
Condition % Degradation 
Purity            
angle 
Purity 
threshold 
Purity   
Flag 
Unstressed Test 
sample 
Unstress 
- 0.091 0.257 No 
Thermal 80°C for 72 hours 0.06 0.089 0.267 No 
Photolytic 
1.2million LUX Hours & 
200 watt hours/square meter 0.05 0.086 0.270 No 
Acid  
5N HCl / 2 hours heating at 
80°C 14.5 0.069 0.300 No 
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Base 
0.5N NaOH / 45mins heating 
at 70°C 2.6 0.107 1.990 No 
Oxidation 
3%H2O2 / 50mins heating at 
80°C 4.2 0.102 0.282 No 
No peaks were detected at the retention time of the related substances and Mebendazole peak in 
the chromatogram of the Diluent / mobile phase and placebo solutions. 
Peak purity angle was less than Peak purity threshold for Mebendazole peak in stressed test 
solution. 
There was no tick mark in the purity flag column. Method is specific and stability indicating. 
Observation: 
1. Blank solution, one peak was eluted at 4.1minutes. 
2. No peak was eluted in placebo solution (Unstress) 
Results obtained from forced degradation studies for Active Pharmaceutical 
Ingredient are summarised in Table 44. 
     Table 44:    
Mode of 
degradation 
Condition % Degradation 
Purity         
angle 
Purity 
threshold 
Purity   
Flag 
Unstressed API Un stress 
- 0.085 0.250 No 
Thermal 80°C for 72 hours 0.03 0.077 0.252 No 
Photolytic 
1.2million LUX Hours & 
200 watt hours/square 
meter 
0.41 0.069 0.254 No 
Acid  
5N HCl / 2 hours heating 
at 80°C 16.5 0.060 0.328 No 
Base 
0.5N NaOH / 45mins 
heating at 70°C 1.37 0.092 0.299 No 
Oxidation 
3%H2O2 / 50mins 
heating at 80°C 45.2 0.078 0.258 No 
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No peaks were detected at the retention time of the related substances and 
Mebendazole peak in the chromatogram of the Diluent / mobile phase and placebo 
solutions. 
Peak purity angle was less than Peak purity threshold for Mebendazole peak in 
stressed test solution. 
There was no tick mark in the purity flag column. Method is specific and stability 
indicating. 
 Observation: 
1. Blank peak was eluted at RT about 4.1minutes. 
2. Acid stress condition unknown impurity at RT 22.347minutes were 
increased. Eighteen new peaks were observed in acid stress condition (5N HCl). 
 Conclusion 
 The results prove that the method is stability indicating of the Mebendazole.  
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System Suitability Tests 
Stability of solutions: Test Results and Acceptance Criteria 
The system suitability tests results generated during method validation are listed and evaluated 
Table 459: System Suitability tests results 
Date Validation 
Charac-
teristic 
Result 
set ID 
mg / mL 
Reference 
Solution 1 
Mean  
Area 
Count 
µV.sec 
(n = 5) 
RT  
Area  
Count 
µV.sec 
Recovery 
RT 
80.0-
120.0% 
mg / mL 
Reference 
Solution 2 
Area 
Count 
µV.sec 
Reference 
Solution 2 
Recovery 
Ref Sol 2 
98.0-
102.0% 
Area 
Count 
µV.sec 
Control  
Reference 
Recovery 
Control 
Reference 
98.0-
102.0% 
03/06/2013 Specificity NA 0.09994 2838964 3099 109.2 0.10002 2868110 100.9 2869913 101.1 
05/06/2013 STS-0 day NA 0.09986 2819491 2938 104.2 0.09982 2829735 100.4 2830630 100.4 
05/06/2013 Linearity NA 0.09986 2847073 3057 107.4 0.09982 2887172 101.4 2874811 101.0 
05/06/2013 
RB-Spl 
preparation 
Variable 
NA 0.09986 2835876 3038 107.1 0.09982 2829324 99.8 2844750 100.3 
06/06/2013 STS-1 day NA 0.09972 2834965 2951 104.1 0.09976 2840990 100.2 2840879 100.2 
06/06/2013 RB-CHP- Unchanged NA 0.09972 2921907 3024 103.5 0.09976 2950702 100.9 2929883 100.3 
06/06/2013 
RB-Flow-
CHP- 
1.3mL/min 
NA 0.09972 3383815 3645 107.7 0.09976 3396476 100.3 3371918 99.6 
06/06/2013 
RB-Flow-
CHP- 
1.7mL/min 
NA 0.09972 2562919 2725 106.3 0.09976 2559340 99.8 2566937 100.2 
07/06/2013 STS-2 day NA 0.09986 2870824 3000 104.5 0.09996 2869904 99.9 2873723 100.1 
08/06/2013 STS-3 day NA 0.09980 2849959 3322 116.6 0.09982 2849337 100.0 2862286 100.4 
08/06/2013 
RB-CHP-
Column   
temp. 35°C 
NA 0.09986 2880316 3097 107.5 0.09996 2891394 100.3 2878343 99.9 
08/06/2013 
RB-CHP-
Column   
temp. 45°C 
NA 0.09986 2881461 3024 104.9 0.09996 2876529 99.7 2872755 99.7 
RB – Robustness, CP – Chrmatographic purity, CHP – Chromatographic parameter, NA – Not applicable, STS – Stability of solution 
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Table 46: System Suitability tests results 
Date Validation 
Charac-
teristic 
Result 
set ID 
mg / mL 
Reference 
Solution 1 
Mean  
Area 
Count 
µV.sec 
(n = 5) 
RT  
Area  
Count 
µV.sec 
Recovery 
RT 
80.0-
120.0% 
mg / mL 
Reference 
Solution 2 
Area 
Count 
µV.sec 
Reference 
Solution 2 
Recovery 
Ref Sol 2 
98.0-
102.0% 
Area 
Count 
µV.sec 
Control  
Reference 
Recovery 
Control 
Reference 
98.0-
102.0% 
08/06/2013 RB-CHP-Column-B NA 0.09980 2950628 3359 113.8 0.09982 2932306 99.4 2963640 100.4 
08/06/2013 
RB-CHP-
Gradient:   
-1 unit 
NA 0.09980 2976542 3369 113.2 0.09982 2971965 99.8 2982542 100.2 
08/06/2013 
RB-CHP-
Gradient:   
+1 unit 
NA 0.09980 2994270 3516 117.4 0.09982 3000111 100.2 2998984 100.2 
10/06/2013 STS-5 day NA 0.09980 2834882 3258 114.9 0.09974 2837975 100.2 2840659 100.2 
11/06/2013 
RB-CHP-
TFA 
0.0225% 
NA 0.09992 2916754 3261 111.8 0.09996 2913261 99.8 2906015 99.6 
11/06/2013 
RB-CHP-
TFA 
0.0275% 
NA 0.09992 2879368 3433 119.2 0.09996 2894881 100.5 2854142 99.1 
11/06/2013 RB-CHP-Exp.No:12 NA 0.09992 3328748 3681 110.6 0.09996 3321165 99.7 3331008 100.1 
11/06/2013 RB-CHP-Exp.No:14 NA 0.09996 3340088 3552 106.3 0.09996 3325950 99.5 3345493 100.2 
12/06/2013 STS-7 day NA 0.09992 2871667 2884 100.4 0.09998 2888148 100.5 2874399 100.1 
15/06/2013 RB-CHP-Exp.No:11 NA 0.10000 3311713 3659 110.5 0.10046 3326641 100.0 3317909 100.2 
15/06/2013 RB-CHP-Exp.No:13 NA 0.10000 3320981 3658 110.1 0.10046 3334616 100.0 3318279 99.9 
17/06/2013 Accuracy-Assay NA 0.09968 2913020 2933 100.7 2952629 0.09974 101.3 2915687 100.1      
RB – Robustness, CP – Chrmatographic purity, CHP – Chromatographic parameter, NA – Not applicable, STS – Stability of solution 
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Table 47: System Suitability tests results 
Date Validation 
Charac-
teristic 
Result 
set ID 
mg / mL 
Reference 
Solution 1 
Mean  
Area 
Count 
µV.sec 
(n = 5) 
RT  
Area  
Count 
µV.sec 
Recovery 
RT 
80.0-
120.0% 
mg / mL 
Reference 
Solution 2 
Area 
Count 
µV.sec 
Reference 
Solution 2 
Recovery 
Ref Sol 2 
98.0-
102.0% 
Area 
Count 
µV.sec 
Control  
Reference 
Recovery 
Control 
Reference 
98.0-
102.0% 
18/06/2013 Accuracy - CP NA 0.10014 2901423 2881 99.3 0.10020 2898106 99.8 2919667 100.6 
19/06/2013 
Reproducib
ility: batch 
Smarathe-
02-027 
NA 0.10030 2887844 3282 113.6 0.10040 2893031 100.1 2888719 100.0 
19/06/2013 Filter study 
 
NA 
 
0.10030 2887844 3282 113.6 0.10040 2893031 100.1 2889145 100.0 
20/06/2013 Quantitatio
n Limit 
NA 0.09994 2801491 2860 102.1 0.09984 2800890 100.1 2800711 100.0 
20/06/2013 
Reproducib
ility: batch 
Smarathe-
02-025/03 
NA 0.09994 2889659 2753 95.3 0.09984 2886705 100.0 2898616 100.3 
21/06/2013 Linearity  NA 0.09970 2759574 2993 108.5 0.09976 2759310 99.9 2789781 101.1 
RB – Robustness, CP – Chrmatographic purity, CHP – Chromatographic parameter, NA – Not applicable, STS – Stability of solution 
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Table 48: System Suitability tests results (continued) 
Date Validation 
Charac-teristic 
Result 
set ID 
Resolution 
Rs** ≥ 2.5 
Tailing Factor** 
< 2.0 
%RSD*  
(n = 5) 
≤ 1.0% 
03/06/2013 Specificity NA 6.3 1.0 0.7 
05/06/2013 STS-0 day NA 6.4 1.0 0.4 
05/06/2013 Linearity NA 6.5 1.0 0.2 
05/06/2013 
RB-Spl 
preparation 
Variable 
NA 6.8 1.0 0.1 
06/06/2013 STS-1 day NA 6.4 1.0 0.1 
06/06/2013 RB-CHP- Unchanged NA 6.4 1.0 1.0 
06/06/2013 RB-Flow-CHP- 1.3mL/min NA 6.6 1.0 0.5 
06/06/2013 RB-Flow-CHP- 1.7mL/min NA 6.4 1.0 0.2 
07/06/2013 STS-2 day NA 7.0 1.0 0.1 
08/06/2013 STS-3 day NA 6.3 1.0 0.1 
08/06/2013 RB-CHP-Column   temp. 35°C NA 6.2 1.0 0.1 
08/06/2013 RB-CHP-Column   temp. 45°C NA 7.4 1.0 0.1 
*: Relative Standard Deviation for the areas of the 5 successive injections of Reference Solution 1 
**: Rs – As at begin of each sequence 
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Table 4910: System Suitability tests results (continued) 
Date Validation 
Charac-teristic 
Result 
set ID 
Resolution 
Rs** ≥ 2.5 
Tailing Factor** 
< 2.0 
%RSD*  
(n = 5) 
≤ 1.0% 
08/06/2013 RB-CHP-Column-B NA 6.5 1.0 0.3 
08/06/2013 RB-CHP-Gradient:   -1 unit NA 6.7 1.0 0.1 
08/06/2013 
RB-CHP-
Gradient:   +1 
unit 
NA 6.5 1.0 0.1 
10/06/2013 STS-5 day NA 6.3 1.0 0.1 
11/06/2013 RB-CHP-TFA 0.0225% NA 7.5 1.0 0.2 
11/06/2013 RB-CHP-TFA 0.0275% NA 6.9 1.0 1.0 
11/06/2013 RB-CHP-Exp.No:12 NA 8.2 1.0 0.1 
11/06/2013 RB-CHP-Exp.No:14 NA 6.7 1.0 0.1 
12/06/2013 STS-7 day NA 7.3 1.0 0.1 
15/06/2013 RB-CHP-Exp.No:11 NA 7.4 1.0 0.1 
15/06/2013 RB-CHP-Exp.No:13 NA 5.9 1.0 0.1 
17/06/2013 Accuracy-Assay NA 7.2 1.0 0.6 
*: Relative Standard Deviation for the areas of the 5 successive injections of Reference Solution 1 
**: Rs – As at begin of each sequence 
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Table 5011: System Suitability tests results (continued) 
Date Validation 
Charac-teristic 
Result 
set ID 
Resolution 
Rs** ≥ 2.5 
Tailing Factor** 
< 2.0 
%RSD*  
(n = 5) 
≤ 1.0% 
18/06/2013 Accuracy - CP NA 7.1 1.0 0.2 
19/06/2013 
Reproducibility: 
batch Smarathe-
02-027 
NA 6.6 1.0 0.1 
19/06/2013 Filter study NA 6.6 1.0 0.1 
20/06/2013 Quantitation Limit NA 7.1 1.0 0.1 
20/06/2013 
Reproducibility: 
batch Smarathe-
02-025/03 
NA 6.6 1.0 0.1 
21/06/2013 Linearity NA 7.0 1.0 0.2 
*: Relative Standard Deviation for the areas of the 5 successive injections of Reference Solution 1 
**: Rs – As at begin of each sequence 
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CONCLUSION: 
This method validation report describes the results and acceptance criteria for the 
validation of DS-TMD-12345, Version: 1.0. 
Since all the acceptance criteria have been met the report demonstrates that the test 
method is suitable for identification and assay of R017635 and determination of its 
impurities in R017635 G002, Mebendazole Chewable 500mg Tablets. 
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   RESULTS AND DISCUSSION 
The objective of the proposed work was to develop a simple, reliable method 
for the determination of Mebendazole to validate the methods according to USP and 
ICH Guidelines Q2(R1) and applying the same for its estimation in laboratory 
prepared mixtures.  
In this method, HPLC conditions were optimized to obtain, an adequate 
separation of eluted compounds. Initially, various mobile phase compositions were 
tried, to separate the title ingredient. Mobile phase and flow rate selection was based 
on peak parameters (height, tailing, theoretical plates, capacity or symmetry factor), 
run time, retention time and resolution. The system with Phosphate buffer: Methanol 
(pH 2.5±0.1) (70:30 v/v) with 0.8ml.min-1 flow rate is quite healthy. 
The optimum wavelength for detection was 254nm at which better detector 
response for the title drug was obtained. The retention time for was found to be 
4.1min. The calibration was linear in concentration range of 1-10 µg mL-1 
withregression 0.999, intercept +2056 and slope 18593. 
Sample to sample precision and accuracy were evaluated using six samples 
of one concentration, which were prepared and analyzed on same day. Day to day 
variability was assessed using oneconcentration analyzed on two different days. 
These results show the precision and accuracy of the assay based on % R.S.D.(0.82 
– 0.96%) reported was found to be less than 2% and recovery (99.9 – 100.25%) 
were found to be in the range of 98 – 102%.The proposed method was validated in 
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accordance with ICH parameters and the applied for analysis of the same in 
laboratory prepared mixtures.   
Thus the proposed method is NEW, accurate, simple, rapid and selective for 
the estimation of Mebendazolein laboratory prepared mixtures.Hence, these 
methods can be conveniently adopted for the routine analysis of Mebendazole 
formulation in quality control laboratories. 
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SUMMARY 
Summary: 
On the basis of the experiment, I can conclude that the RP-HPLC 
method developed for the Estimation of Mebendazolecan be used for routine 
analysis Quality Control (QC) Samples. 
Mebendazoleis determined by reverse phase HPLC using, 
1. Column: Zorbax SB C18 (150×4.6) mm, id 5.0µm particle size or equivalent 
2. Column Temperature : 40°C ± 2.0°C 
3. Auto-sampler Temperature : 5°C 
4. Flow rate : 1.50 mL/min 
5. Injection volume : 10 µL 
6. Detection : UV at 250 nm 
7. Run time : 35 minutes 
8. Elution mode : Gradient elution 
Buffer 0.025% Trifluoro Acetic Acid: Acetonitrile combination as mobile 
phase in gradient programme. 
A linear gradient is programmed as described in the following table; 
Time(min.) 0 20 29 30 35 
% A 90 70 30 90 90 
% B 10 30 70 10 10 
After development of the method, it was validated for system suitability, specificity 
and linearity, limit of detection and limit of quantification, precision, and accuracy. 
 The system suitability was found to be within the limits. The percent relative 
standard deviation (% RSD) for the area for Mebendazole of five 
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replicateinjections of the Reference Solution 1 should be less than or equal 
to 2.0 %. The per cent relative standarddeviation (% RSD) for the area for 
Mebendazole is 0.2. 
 The percentage recovery of Mebendazole in Reference Solution 2is 98.0% 
≤ % Recovery ≤ 102.0%. The percentage recovery of Mebendazole is 98.6. 
 The tailing factor (T) for the Mebendazole peak from first replicate of 
reference solution must be less than 2.0, as calculated by the current USP 
method. The tailing factor (T) for the Mebendazole peak is 1.0. 
 The Resolution factor (R) between (R019020 and R017635) in the 
selectivity solution must be greater than 2.5 calculated by current USP 
method. The Resolution factor (R) between (R019020 and R017635) is 4.6. 
 The reference solution must be injected as a calibration check after each 
series of maximum 12 sample injections and after the last sample injection. 
The percentage Recovery of Mebendazole is 98.0% ≤ % Recovery ≤ 
102.0%. The percentage Recovery of Mebendazole is 98.6. 
 The limit were Not more than RSD <2%. The retention time of 
Mebendazole is 17.3mins.  
 The precision was found to be within the limits. The limit were not more 
than RSD <2%. This indicates that the method is precise. The data 
regarding the precision are shown in Table no 8 and 9. 
 From the linearity table, it was found that, the drug obeys Beer’s Law. For 
HPLC the calibration plot of Mebendazole was observed as linear in the 
range 0.1-120 mg/mL and the correlation coefficient were found to be 
0.999. 
 From the results shown in the accuracy table and, it was found thatrecovery 
value of pure drug from the solution were between 98%to102% Which 
indicates that the method is accurate. 
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Table 51: Summary of the present study (RP-HPLC) 
Validation Parameters Mebendazole (R017635) 
Mobile phase 0.025% Trifluoro acetic 
Acid:ACN(90:10, v/v) 
(In gradient programme) 
Flow rate 1.5 mL/min 
Detection Wavelength 250 nm 
Retention Time About 17 minutes 
Run Time 35 min 
USP Resolution factor 4.6 
LOD for Mebendazole 
LOD for R018986 
0.01% 
0.003% 
LOQ  for Mebendazole 
LOQ for R018986 
0.02% 
0.01% 
Linearity  for Mebendazole 
Linearity  for Mebendazole 
Linearity  for R018986 
0.10-120.0%, R=0.999 
80.0-120.0%, R=0.999 
0.10-1.0%, R=0.999 
Precision  for batch: smarathe-02-027 
Precision  for  Mebendazole 
Precision  for R018986 
 
0.3%  (%RSD ≤ 2.0) 
0.3% (%RSD ≤ 5.0) 
Precision  for batch: smarathe-02-025/03 
Precision  for  Mebendazole 
Precision  for R018986. 
 
0.3% (%RSD ≤ 2.0) 
0.4% (%RSD ≤ 5.0) 
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Recovery (Accuracy) 
Accuracy Mebendazole 80.0%                        - 100.2, 101.0, 101.7 (97.0-103.0%) 
- 101.0 (98.0-102.0) 
Accuracy Mebendazole 100.0%                        - 101.6, 101.3, 101.4 (99.7-103.0%) 
- 101.4 (98.0-102.0) 
  
Accuracy Mebendazole 120.0%                        - 99.6, 101.2, 101.0 (99.7-103.0%) 
- 100.6 (98.0-102.0) 
 
Accuracy Mebendazole0.10%                     -110.5 (80.0-120.0) 
 
Accuracy Mebendazole 0.50%                        -101.0 (90.0-110.0) 
 
Accuracy Mebendazole 0.10%                        -101.0 (90.0-110.0) 
 
Accuracy R018986 0.10%                               -101.9 (80.0-120.0) 
 
Accuracy R018986 0.50%                               -98.8 (90.0-110.0) 
 
Accuracy R018986 0.10%                               -98.3 (90.0-110.0) 
 
Mebendazole                                                   - Stable for 7 days in BT 
Condition 
 
Range                                                               - 0.10% 120.0% 
     Conclusion  
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CONCLUSION 
 The proposed method was found to be simple, precise, accurate and rapid 
for determination of Mebendazole, in pure form. 
 The mobile phase is simple to prepare and economical.  
 The sample recoveries in all formulations were in good agreement within 
the limit. 
 Hence, this method can be easily and conveniently adopted for routine 
analysis of Mebendazole. 
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